RayKnowChina Research Map
Shortlist0

NanjingNanjing Medical University

Jiangsu Province Hospital

江苏省人民医院(南医大一附院)

Listed for 34 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Jiangsu Province Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌11 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌36 papers led8 open trials led
  3. Hepatocellular carcinoma肝细胞癌117 papers led5 open trials led
  4. Stomach cancer胃癌199 papers led23 open trials led
  5. Retinoblastoma视网膜母细胞瘤0 papers led
  6. Chordoma脊索瘤1 paper led
  7. Osteosarcoma骨肉瘤4 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤14 papers led1 open trial led
  9. Neuroblastoma神经母细胞瘤8 papers led2 open trials led
  10. Ewing sarcoma尤文肉瘤0 papers led
  11. Multiple myeloma多发性骨髓瘤24 papers led6 open trials led
  12. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病0 papers led1 open trial led
  13. Aplastic anaemia再生障碍性贫血9 papers led
  14. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症22 papers led
  15. Beta thalassaemiaβ 地中海贫血1 paper led
  16. Haemophilia A血友病 A0 papers led
  17. Myasthenia gravis重症肌无力4 papers led
  18. Moyamoya disease烟雾病3 papers led3 open trials led
  19. Takayasu arteritis大动脉炎2 papers led
  20. Idiopathic pulmonary fibrosis特发性肺纤维化10 papers led
  21. Amyotrophic lateral sclerosis肌萎缩侧索硬化症4 papers led
  22. Fabry disease法布雷病1 paper led
  23. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  24. Behçet disease白塞病0 papers led
  25. IgA nephropathyIgA 肾病2 papers led
  26. Gaucher disease戈谢病1 paper led
  27. Osteogenesis imperfecta成骨不全症1 paper led
  28. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  29. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  30. Hirschsprung disease先天性巨结肠0 papers led
  31. Inherited epidermolysis bullosa遗传性大疱性表皮松解症0 papers led
  32. Hereditary angioedema遗传性血管性水肿0 papers led
  33. Familial adenomatous polyposis家族性腺瘤性息肉病2 papers led
  34. Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led

Not listed for: Hepatoblastoma, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Pompe disease, Alport syndrome, Niemann–Pick disease type C, Congenital diaphragmatic hernia, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 11 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 3320232024: 3320242025: 222025

4 hospitals in Nanjing for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AIInduction / concurrent chemotherapy
Departments in papersRadiation oncologyENT / head & neck surgery
Papers it led11
  1. The Impact of Whole-Course Immunonutrition Management on Patients With Stage III and IV Nasopharyngeal Carcinoma Undergoing Concurrent Chemoradiotherapy: A Randomized Controlled Trial.2025Nutrition and cancerRCT
  2. Radiomic analysis based on machine learning of multi-sequences MR to assess early treatment response in locally advanced nasopharyngeal carcinoma.2025Science progressFree full text
  3. Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma.2024Oral oncology
  4. Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.2024Oral oncology
  5. Improving the performance of deep learning models in predicting and classifying gamma passing rates with discriminative features and a class balancing technique: a retrospective cohort study.2024Radiation oncology (London, England)Free full text
  6. Predicting prognosis of nasopharyngeal carcinoma based on deep learning: peritumoral region should be valued.2023Cancer imaging : the official publication of the International Cancer Imaging SocietyFree full text
  7. RASSF1A promotes radiosensitivity in nasopharyngeal carcinoma by promoting FoxO3a and inhibiting the Nrf2/TXNRD1 signaling pathway.2023Neoplasma
  8. Identification and verification of aging-related lncRNAs for prognosis prediction and immune microenvironment in patients with head and neck squamous carcinoma.2023Oncology researchFree full text
  9. LINC00240 knockdown inhibits nasopharyngeal carcinoma progress by targeting miR-26a-5p.2022Journal of clinical laboratory analysisFree full text
  10. c-Myc-induced circ-NOTCH1 promotes aggressive phenotypes of nasopharyngeal carcinoma cells by regulating the miR-34c-5p/c-Myc axis.2021Cell biology international
  11. The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis.2021MedicineFree full text
All its trials on ClinicalTrials.gov, any status1
  1. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
More papers found outside PubMed (not counted)16
  1. WITHDRAWN: 1386P A deep learning-based time-habitat longitudinal MRI radiomics model for predicting short-term treatment outcomes in locally advanced nasopharyngeal carcinoma: A multi-center study2025Annals of Oncologyretraction
  2. 897P Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma2024Annals of Oncologyarticle
  3. 928P Radiomic analysis based on machine learning of multi-MR sequences to assess early treatment response in locally advanced nasopharyngeal carcinoma2024Annals of Oncologyarticle
  4. 931P Deep learning models for predicting short-term efficacy in locally advanced nasopharyngeal carcinoma2024Annals of Oncologyarticle
  5. Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  6. Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  7. Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  8. Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  9. Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  10. Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  11. Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  12. Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  13. Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop2022Figsharedataset
  14. Clinical Observation of Three Dimensional Conformal Intensity-modulated Radiotherapy Combined with Cisplatin Chemotherapy and Nituzumab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma2021Advances in Modern Oncology Researcharticle
  15. Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase2021Figsharedataset
  16. MA13.08 CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 36 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
36
2021–2025
Trials led
10
any status, ClinicalTrials.gov
Open trials led
8
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 101020212022: 4420222023: 7720232024: 9920242025: 552025

5 hospitals in Nanjing for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06356688

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  2. Recruiting
    Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
    Phase
    Phase 3
    Started
    2024-02
    Registry
    NCT06563869

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  3. Recruiting
    Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06698692

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  4. Recruiting
    Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2024-03
    Registry
    NCT06988956

    Age 75 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  5. Recruiting
    Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
    Phase
    Phase 2
    Started
    2023-12
    Registry
    NCT06354218

    Age 75 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  6. Recruiting
    Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC
    Phase
    N/A
    Started
    2021-06
    Registry
    NCT05775419

    Age 18 years to 70 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  7. Enrolling by invitation
    Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07371247

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  8. Enrolling by invitation
    Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2022-07
    Registry
    NCT06048926

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  9. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesChangchun, Chengdu, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou

  10. Recruiting
    Chemoradiotherapy in Unresectable Esophageal Cancer
    Phase
    Phase 1/Phase 2
    Started
    2019-10
    Registry
    NCT04278287

    Age 18 years to 75 years (registered criteria)

    Led by National Cancer Center / Cancer Hospital, CAMS; 4 listed hospitals as study sitesAnyang, Beijing, Changsha, Nanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapyImaging & AIMolecular markers & genomics
Departments in papersRadiation oncologyMedical oncologyGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led36
  1. Development and validation of an interpretable Random Forest model for predicting recurrence after endoscopic submucosal dissection in superficial oesophageal squamous cell carcinoma.2026Annals of medicineFree full text
  2. Efficacy of local radiotherapy in first-line treatment of recurrent or metastatic esophageal squamous cell carcinoma based on immunotherapy.2025BMC cancerFree full text
  3. Development and validation of a novel artificial intelligence algorithm for precise prediction the postoperative prognosis of esophageal squamous cell carcinoma.2025BMC cancerFree full text
  4. Real-World Assessment of Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Study.2025Cancer medicineFree full text
  5. Machine Learning-Based Glycolipid Metabolism Gene Signature Predicts Prognosis and Immune Landscape in Oesophageal Squamous Cell Carcinoma.2025Journal of cellular and molecular medicineFree full text
  6. Endoscopic ultrasound-based radiomics for predicting pathologic upgrade in esophageal low-grade intraepithelial neoplasia.2025Surgical endoscopy
  7. Development and Validation of an 18F-FDG PET/CT-based Radiomics Nomogram for Predicting the Prognosis of Patients with Esophageal Squamous Cell Carcinoma.2024Academic radiology
  8. Induction Therapy of Tislelizumab Combined with Cisplatin and 5-Fluorouracil and Subsequent Conversion Surgery in Patients with Unresectable Advanced Esophageal Squamous Cell Carcinoma: A Phase 2, Single Center Study.2024Annals of surgical oncology
  9. Survival risk stratification based on prognosis nomogram to identify patients with esophageal squamous cell carcinoma who may benefit from postoperative adjuvant therapy.2024BMC cancerFree full text
  10. Characteristics of the oral and gastric microbiome in patients with early-stage intramucosal esophageal squamous cell carcinoma.2024BMC microbiologyFree full text
  11. DNA polymerase iota promotes EMT and metastasis of esophageal squamous cell carcinoma by interacting with USP7 to stabilize HIF-1α.2024Cell death & diseaseFree full text
  12. Multidisciplinary treatment of synchronous primary advanced gastric adenocarcinoma and esophageal squamous cell carcinoma-a retrospective single-institution study.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  13. Peripheral blood lymphocyte subpopulations as predictive biomarkers for first-line programmed death 1 inhibitors efficacy in esophageal squamous cell carcinoma: A retrospective study.2024MedicineFree full text
  14. FAP positive cancer-associated fibroblasts promote tumor progression and radioresistance in esophageal squamous cell carcinoma by transferring exosomal lncRNA AFAP1-AS1.2024Molecular carcinogenesis
  15. Hypoxia inhibits ferritinophagy-mediated ferroptosis in esophageal squamous cell carcinoma via the USP2-NCOA4 axis.2024Oncogene
  16. A SARS-CoV-2 related signature that explores the tumor microenvironment and predicts immunotherapy response in esophageal squamous cell cancer.2023AgingFree full text
  17. circFNDC3B promotes esophageal squamous cell carcinoma progression by targeting MYO5A via miR-370-3p/miR-136-5p.2023BMC cancerFree full text
  18. Integrative analysis of negatively regulated miRNA-mRNA axes for esophageal squamous cell carcinoma.2023Cancer biomarkers : section A of Disease markersFree full text
  19. Cancer-testis non-coding RNA LEF1-AS1 regulates the nuclear translocation of PDCD5 and suppresses its interaction with p53 signaling: a novel target for immunotherapy in esophageal squamous cell carcinoma.2023Carcinogenesis
  20. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.2023Frontiers in immunologyFree full text
  21. Predictive values of the hemoglobin, albumin, lymphocyte and platelet score (HALP) and the modified -Gustave Roussy immune score for esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy.2023International immunopharmacology
  22. Oral microbiota may predict the presence of esophageal squamous cell carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  23. Prognostic factors for 495 nonoperative esophageal squamous cancer patients receiving IMRT plus chemotherapy: A retrospective analysis.2022Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  24. lncRNA BBOX1-AS1 silencing inhibits esophageal squamous cell cancer progression by promoting ferroptosis via miR-513a-3p/SLC7A11 axis.2022European journal of pharmacology
  25. Combined assessment of tumour cell nest size and desmoplastic reaction as an excellent prognostic predictor in oesophageal squamous cell carcinoma.2022Histopathology
  26. Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop.2022Journal of experimental & clinical cancer research : CRFree full text
  27. LncRNA LOC146880 promotes esophageal squamous cell carcinoma progression via miR-328-5p/FSCN1/MAPK axis.2021AgingFree full text
  28. Development and validation of nomograms to intraoperatively predict metastatic patterns in regional lymph nodes in patients diagnosed with esophageal cancer.2021BMC cancerFree full text
  29. Elevated TAB182 enhances the radioresistance of esophageal squamous cell carcinoma through G2-M checkpoint modulation.2021Cancer medicineFree full text
  30. A comparison between raltitrexed plus cisplatin and docetaxel plus cisplatin in concurrent chemoradiation for non-surgical esophageal squamous cell carcinoma.2021Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
  31. Development and validation of a new clinical staging system to predict survival for esophageal squamous cell carcinoma patients: Application of the nomogram.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  32. Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma.2021Frontiers in cellular and infection microbiologyFree full text
  33. The ATPase subunit of ATP6V1C1 inhibits autophagy and enhances radiotherapy resistance in esophageal squamous cell carcinoma.2021Gene
  34. Hypoxic tumour cell-derived exosomal miR-340-5p promotes radioresistance of oesophageal squamous cell carcinoma via KLF10.2021Journal of experimental & clinical cancer research : CRFree full text
  35. Risk prediction nomogram for major morbidity related to primary resection for esophageal squamous cancer.2021MedicineFree full text
  36. CDCA2 promotes tumorigenesis and induces radioresistance in oesophageal squamous cell carcinoma cells.2021Molecular medicine reportsFree full text
Chinese-language papers (not in the count)1
  1. [Clinical efficacy of anlotinib plus S-1 as a second-line therapy for recurrent or metastatic esophageal squamous cell carcinoma].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status21
  1. Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and EfficacyEnrolling by invitationNCT07371247Lead sponsorEarly phase 1Start 2025-12
  2. Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT06988956Lead sponsorPhase 2Start 2024-03
  3. Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell CarcinomaRecruitingNCT06698692Lead sponsorStart 2024-04
  4. Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell CarcinomaRecruitingNCT06563869Lead sponsorPhase 3Start 2024-02
  5. Serplulimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old AgeRecruitingNCT06354218Lead sponsorPhase 2Start 2023-12
  6. Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell CarcinomaEnrolling by invitationNCT06048926Lead sponsorN/AStart 2022-07
  7. Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCCRecruitingNCT05775419Lead sponsorN/AStart 2021-06
  8. Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCCStatus unknownNCT05469061Lead sponsorPhase 2Start 2022-01
  9. Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal CancerStatus unknownNCT03946969Lead sponsorPhase 2Start 2019-05
  10. A Clinical Study on the Efficacy and Safety of Paclitaxel Polymeric Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06356688Lead (inferred)Phase 2Start 2025-04
  11. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  12. Chemoradiotherapy in Unresectable Esophageal CancerRecruitingNCT04278287Study sitePhase 1/Phase 2Start 2019-10
  13. A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Study sitePhase 1Start 2024-08
  14. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  15. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
  16. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  17. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  18. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  19. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  20. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)CompletedNCT02649361Study sitePhase 2Start 2016-01
  21. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
More papers found outside PubMed (not counted)58
  1. 271O Final analysis and biomarker evaluation of JUPITER-06: A phase III trial of toripalimab plus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma2025Annals of Oncologyarticle
  2. A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy with or witho2025Figsharesupplementary-materials
  3. Additional file 1 of A nomogram integrating machine learning-derived CT radiomics and clinical characteristics for prognostic assessment in patients with locally advanced esophageal squamous cell carcinoma treated with definitive chemoradio2025Figsharearticle
  4. Correlation between Histogram Analysis Parameters Derived from DCE-MRI and the Expression of PD-L1 in Esophageal Squamous Cell Carcinoma. A Preliminary Study2025Research Reviewarticle
  5. Fruquintinib in combination with camrelizumab and paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II study.2025Journal of Clinical Oncologyconference-abstract
  6. Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial.2025Journal of Clinical Oncologyconference-abstract
  7. Photodynamic Therapy as a Promising Treatment for Long-segment and Whole-circumferential Early Esophageal Cancer2025Photodiagnosis and Photodynamic Therapyarticle
  8. Preliminary results of the ALTER-E009 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC)—A multicenter, multi-cohort retrospective exp2025Journal of Clinical Oncologyconference-abstract
  9. Updated results of the ALTER-E00 study: Efficacy and safety of anlotinib combined with radiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A multi-center, multi-cohort retrospective explor2025Journal of Clinical Oncologyarticle
  10. 395MO Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-3062024Annals of Oncologyarticle
  11. ALOX12B and PRMT5 inhibit stemness and EMT in esophageal squamous cell carcinoma by promoting decorin expression2024Research Squarepreprint
  12. Abstract CT213: Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2024Cancer Researchconference-abstract
  13. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C.2024Journal of Clinical Oncologyconference-abstract
  14. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C.2024Journal of Clinical Oncologyconference-abstract
  15. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from multi-cohort, multi-center phase II trial ALTER-G-001-cohort A.2024Journal of Clinical Oncologyconference-abstract
  16. Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).2024Journal of Clinical Oncologyconference-abstract
  17. Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow2024Journal of Clinical Oncologyconference-abstract
  18. PCR65 Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality of Life (HRQoL) Outcomes in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC): The Rationale-306 Study2024Value in Healthconference-abstract
  19. Tislelizumab plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy for elderly patients with inoperable locally advanced esophageal squamous cell carcinoma: A multicenter, randomized, parallel-controlled, phase II clinical t2024Journal of Clinical Oncologyconference-abstract
  20. “Pacific” Modality in Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis of a Real-World Multicenter Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  21. 103P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A2023Annals of Oncologyarticle
  22. 150P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C2023Annals of Oncologyarticle
  23. 1514P Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update2023Annals of Oncologyarticle
  24. 1628P Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Preliminary results from a multi-cohort, multi-center phase II trial (ALTER-G-001)2023Annals of Oncologyarticle
  25. Abstract CT075: Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-2023Cancer Researchconference-abstract
  26. Additional file 1 of Hypoxia-induced TMTC3 expression in esophageal squamous cell carcinoma potentiates tumor angiogenesis through Rho GTPase/STAT3/VEGFA pathway2023Figsharedataset
  27. Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  28. Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  29. Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  30. Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma2023Figsharedataset
  31. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Results from a multi-cohort, multicenter phase II trial (ALTER-G-001).2023Journal of Clinical Oncologyconference-abstract
  32. Identification of secretory factors associated with suppressive tumor microenvironment in esophageal cancer2023Research Squarepreprint
  33. 132TiP Dose escalation of chemoradiotherapy in locally advanced esophageal squamous cell carcinoma based on positron emission tomography response: A phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)2022Annals of Oncologyarticle
  34. 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup2022Annals of Oncologyarticle
  35. Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  36. Additional file 10 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  37. Additional file 11 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  38. Additional file 12 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  39. Additional file 13 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  40. Additional file 14 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  41. Additional file 15 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  42. Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  43. Additional file 2 of Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma2022Figsharedataset
  44. Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  45. Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration2022Figsharedataset
  46. Additional file 7 of Heparanase is a prognostic biomarker independent of tumor purity and hypoxia based on bioinformatics and immunohistochemistry analysis of esophageal squamous cell carcinoma2022Figsharedataset
  47. Additional file 9 of Irradiation induces DJ-1 secretion from esophageal squamous cell carcinoma cells to accelerate metastasis of bystander cells via a TGF-β1 positive feedback loop2022Figsharedataset
  48. Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: A multicenter, multicohort clinical trial (ALTER-G-001).2022Journal of Clinical Oncologyconference-abstract
  49. Concurrent Chemoradiation of Different Doses (50.4 Gy vs. 59.4 Gy) and Different Target Field (ENI vs. IFI) for Locally Advanced Esophageal Squamous Cell Carcinoma: Results from a Randomized, Multicenter Phase Ⅲ Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  50. Effectiveness of S-1–Based Chemoradiotherapy and S-1 Consolidation in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Multicenter Randomized Phase III Clinical Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  51. LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)2022Annals of Oncologyarticle
  52. Long non-coding RNA NCK1-AS1 functions as a ceRNA to regulate cell viability and invasion in esophageal squamous cell carcinoma via microRNA-133b/ENPEP axis2022Figsharedataset
  53. P-100 CXCL8 is a valid potential prognostical marker for esophageal squamous cell carcinoma2022Annals of Oncologyconference-abstract
  54. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)2021Annals of Oncologyarticle
  55. LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study2021Annals of Oncologyconference-abstract
  56. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  57. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  58. RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 117 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
117
2021–2025
Trials led
10
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 8820212022: 282820222023: 181820232024: 323220242025: 27272025

7 hospitals in Nanjing for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After Surgery
    Phase
    Phase 2
    Started
    2025-02
    Registry
    NCT06762782

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  2. Recruiting
    Immunotherapy for Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT06241326

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  3. Recruiting
    Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
    Phase
    Phase 3
    Started
    2023-01
    Registry
    NCT05613478

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  4. Recruiting
    Goal-directed LCVP Based on HP in Laparoscopic Hepatectomy
    Phase
    N/A
    Started
    2022-05
    Registry
    NCT05887661

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  5. Not yet recruiting
    A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-08
    Registry
    NCT07131501

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  6. Recruiting
    MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)
    Phase
    Phase 1/Phase 2
    Started
    2026-04
    Registry
    NCT07479485

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Fuzhou, Nanjing, Tianjin, Zhengzhou

  7. Recruiting
    Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
    Phase
    Phase 1
    Started
    2025-11
    Registry
    NCT07176650

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Bengbu, Changchun, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  8. Recruiting
    β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07317414

    Age 18 years to 75 years (registered criteria)

    Led by Peking Union Medical College Hospital; 2 listed hospitals as study sitesBeijing, Nanjing, Xuzhou

  9. Recruiting
    ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07327034

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 39 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shenyang, Tianjin, Wuhan, Xi'an, Xuzhou, Yinchuan, Zhengzhou

  10. Not yet recruiting
    Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma
    Phase
    N/A
    Started
    2026-12
    Registry
    NCT07866612

    Age 18 years to 80 years (registered criteria)

    Led by West China Hospital; 8 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicinePathology / laboratory medicineClinical trials / research unit

Over half of these papers are lab or animal studies.

Papers it led117
  1. Puerarin Targets MIC19 to Suppress Mitochondrial Metabolism of Tumor-Infiltrating Tregs and Enhance Anti-tumor Immunity.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. Gold-embedded yolk-shell mesoporous organosilica nanocomposite for microwave-enhanced targeted chemotherapy and immune modulation in hepatocellular carcinoma.2026Biomaterials
  3. Etomidate Improves Antitumor Immunity by Suppressing PD-L1 Expression in Hepatocellular Carcinoma Cells.2026Cellular and molecular gastroenterology and hepatologyFree full text
  4. Prediction Model of Ki67 Proliferation Level in Hepatocellular Carcinoma Based on Contrast-Enhanced Ultrasound.2026Journal of clinical ultrasound : JCU
  5. Liver tumor imaging staging: a multi-institutional study of a preoperative staging tool for hepatocellular carcinoma.2025Abdominal radiology (New York)Free full text
  6. Comparison of different machine learning methods in the prediction of early recurrence in HCC patients with Gd-EOB-DTPA-MRI.2025Abdominal radiology (New York)
  7. CT-Based Habitat Model for Predicting Tumor Response and Survival in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors.2025Academic radiology
  8. MRI-Based Quantification of Intratumoral Heterogeneity Predicts Response in Hepatocellular Carcinoma Treated with Atezolizumab-Bevacizumab and TACE/HAIC.2025Academic radiology
  9. Prognostic Value of the Vascular Lake Phenomenon in Large Hepatocellular Carcinoma Following Conventional TACE: A Retrospective Study.2025Academic radiology
  10. GALNT7 promotes hepatocellular carcinoma progression by activating the PI3K/AKT signaling pathway via O-glycosylation of MUC13.2025Acta biochimica et biophysica SinicaFree full text
  11. EIF4A3-Mediated Biogenesis of CircFADS1 Promotes the Progression of Hepatocellular Carcinoma via Wnt/β-Catenin Pathway.2025Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  12. Construction of a radiogenomic signature based on endoplasmic reticulum stress for predicting prognosis and systemic combination therapy response in hepatocellular carcinoma.2025BMC cancerFree full text
  13. Elevated CircYthdc2 expression is correlated with aggressive features and poor progression-free survival in hepatocellular carcinoma.2025BMC gastroenterologyFree full text
  14. Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis.2025Cancer immunology research
  15. O-GlcNAcylation of YBX1 drives a glycolysis-histone lactylation feedback loop in hepatocellular carcinoma.2025Cancer letters
  16. A sub-cluster of cancer cells indicates poor prognosis in advanced hepatocellular carcinoma.2025Chinese clinical oncology
  17. Construction of a prognostic model for hepatocellular carcinoma based on necrosis by sodium overload-related genes and identification of ANKRD13B as a new prognostic marker.2025Functional & integrative genomics
  18. EGR2 promotes liver cancer metastasis by enhancing IL-8 expression through transcription regulation of PDK4 in M2 macrophages.2025International immunopharmacology
  19. SERPINH1 secretion by cancer-associated fibroblasts promotes hepatocellular carcinoma malignancy through SENP3-mediated SP1/SQLE pathway.2025International immunopharmacology
  20. Identification of CACNB1 protein as an actionable therapeutic target for hepatocellular carcinoma via metabolic dysfunction analysis in liver diseases: An integrated bioinformatics and machine learning approach for precise therapy.2025International journal of biological macromolecules
  21. TTC36-Mediated Tumor Suppression via YBX3/SPRED1 Axis Paradoxically Reduces Sorafenib Sensitivity in Hepatocellular Carcinoma.2025International journal of biological sciencesFree full text
  22. Baseline vitamin D status, genetic susceptibility, and the risk of incident hepatocellular carcinoma.2025International journal of cancer
  23. Hypoxia-induced RCOR2 promotes macrophage M2 polarization and CD8+ T-cell exhaustion by enhancing LIF transcription in hepatocellular carcinoma.2025Journal for immunotherapy of cancerFree full text
  24. eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.2025Journal of hepatology
  25. A versatile nanoplatform for enhanced sonodynamic therapy via hypoxia alleviation, glutathione depletion, and calcium overload.2025Journal of materials chemistry. B
  26. Liver elastography-based risk score for predicting hepatocellular carcinoma risk.2025Journal of the National Cancer Institute
  27. Region-guided focal adversarial learning for CT-to-MRI translation: A proof-of-concept and validation study in hepatocellular carcinoma.2025Medical physicsFree full text
  28. LRP11 facilitates lipid metabolism and malignancy in hepatocellular carcinoma by stabilizing RACK1 through USP5 regulation.2025Molecular medicine (Cambridge, Mass.)Free full text
  29. PSME3 drives Tregs infiltration and anti-PD1 resistance in hepatocellular carcinoma by regulating FBXL7/PTEN-mediated metabolic reprogramming.2025Oncogene
  30. Integrated single-cell and spatial transcriptomic profiling reveals that CD177+ Tregs enhance immunosuppression through apoptosis and resistance to immunotherapy in hepatocellular carcinoma.2025Oncogene
  31. Meta-analysis of multimodal analgesia for reducing postoperative wound pain after hepatectomy for hepatocellular carcinoma.2025Scientific reportsFree full text
  32. MRI-based radiomics signature: a potential imaging biomarker for prediction of microvascular invasion in combined hepatocellular-cholangiocarcinoma.2024Abdominal radiology (New York)
  33. Role of Transarterial Chemoembolization in the Era of Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Combination Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective Propensity Score Matched Analysis.2024Academic radiology
  34. GJB2 Promotes HCC Progression by Activating Glycolysis Through Cytoplasmic Translocation and Generating a Suppressive Tumor Microenvironment Based on Single Cell RNA Sequencing.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  35. Transarterial chemoembolization combined with molecular targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma beyond the up-to-seven criteria: a propensity score-matching analysis.2024Annals of medicineFree full text
  36. Prognostic implications of CK19 positivity in patients with early recurrent hepatocellular carcinoma after hepatic resection undergoing transarterial chemoembolization.2024BMC gastroenterologyFree full text
  37. A hypoxia-glycolysis-lactate-related gene signature for prognosis prediction in hepatocellular carcinoma.2024BMC medical genomicsFree full text
  38. Long Non-coding RNA 02298 Promotes the Malignancy of HCC by Targeting the miR-28-5p/CCDC6 Pathway.2024Biochemical genetics
  39. BAIAP2L2 promotes the malignancy of hepatocellular carcinoma via GABPB1-mediated reactive oxygen species imbalance.2024Cancer gene therapyFree full text
  40. CRISPR/Cas9 screen reveals that targeting TRIM34 enhances ferroptosis sensitivity and augments immunotherapy efficacy in hepatocellular carcinoma.2024Cancer letters
  41. RAC1high NK cell-based immunotherapy in hepatocellular carcinoma via STAT3-NKG2D axis.2024Cancer letters
  42. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors Versus Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma with First- or Lower-Ord2024Cardiovascular and interventional radiology
  43. Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma.2024Cell death & diseaseFree full text
  44. Integrated single-cell transcriptomics reveals the hypoxia-induced inflammation-cancer transformation in NASH-derived hepatocellular carcinoma.2024Cell proliferationFree full text
  45. NK cell-based immunotherapy in hepatocellular carcinoma: An attractive therapeutic option for the next decade.2024Cellular signalling
  46. Cuproptosis-associated genes (CAGs) contribute to the prognosis prediction and potential therapeutic targets in hepatocellular carcinoma.2024Cellular signalling
  47. Role of tumor-associated macrophages in hepatocellular carcinoma: impact, mechanism, and therapy.2024Frontiers in immunologyFree full text
  48. Establishment of two novel organoid lines from patients with combined hepatocellular cholangiocarcinoma.2024Human cell
  49. Dexmedetomidine induces IL-10 secretion by B lymphocytes in the peripheral blood of patients with hepatocellular carcinoma.2024Immunobiology
  50. HNF4A-AS1 inhibits the progression of hepatocellular carcinoma by promoting the ubiquitin-modulated degradation of PCBP2 and suppressing the stability of ARG2 mRNA.2024International journal of biological sciencesFree full text
  51. LncRNA ZFAS1 regulates ATIC transcription and promotes the proliferation and migration of hepatocellular carcinoma through the PI3K/AKT signaling pathway.2024Journal of cancer research and clinical oncologyFree full text
  52. The risk stratification and predictive performance of a new combined polygenic risk score for hepatocellular carcinoma.2024Journal of gastroenterology
  53. Efficacy and Safety of TACE Combined with a Tyrosine Kinase Inhibitor for the Treatment of TACE-Refractory Hepatocellular Carcinoma: A Retrospective Comparative Study.2024Journal of gastrointestinal cancer
  54. Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma.2024Journal of hepatology
  55. CircDCAF8 promotes the progression of hepatocellular carcinoma through miR-217/NAP1L1 Axis, and induces angiogenesis and regorafenib resistance via exosome-mediated transfer.2024Journal of translational medicineFree full text
  56. Preoperative Contrast-Enhanced Ultrasound Predicts Microvascular Invasion in Hepatocellular Carcinoma as Accurately as Contrast-Enhanced MR.2024Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  57. Impact of red blood cell distribution width (RDW) on postoperative outcomes in hepatocellular carcinoma (HCC) patients.2024MedicineFree full text
  58. ESRP1-mediated biogenesis of circPTPN12 inhibits hepatocellular carcinoma progression by PDLIM2/ NF-κB pathway.2024Molecular cancerFree full text
  59. Fe-doped Cu-based bimetallic metal-organic frameworks as nanoscale microwave sensitizers for enhancing microwave thermal and dynamic therapy for hepatocellular carcinoma.2024Nanoscale
  60. Molecular insight into T cell exhaustion in hepatocellular carcinoma.2024Pharmacological research
  61. Risk Factors for Early Recurrence After Radical Resection of Hepatocellular Carcinoma Based on Preoperative Contrast-Enhanced Ultrasound and Clinical Features.2024Technology in cancer research & treatmentFree full text
  62. Ultrasound-based Radiomics Analysis for Assessing Risk Factors Associated With Early Recurrence Following Surgical Resection of Hepatocellular Carcinoma.2024Ultrasound in medicine & biology
  63. Early identification of hepatocellular carcinoma patients at high-risk of recurrence using the ADV score: a multicenter retrospective study.2024World journal of surgical oncologyFree full text
  64. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.2023Acta biomaterialia
  65. Seven oxidative stress-related genes predict the prognosis of hepatocellular carcinoma.2023AgingFree full text
  66. ACSL4 serves as a novel prognostic biomarker correlated with immune infiltration in Cholangiocarcinoma.2023BMC cancerFree full text
  67. Etomidate elicits anti-tumor capacity by disrupting the JAK2/STAT3 signaling pathway in hepatocellular carcinoma.2023Cancer letters
  68. The role of tumor-associated macrophages in hepatocellular carcinoma progression: A narrative review.2023Cancer medicineFree full text
  69. Preoperative alpha fetoprotein, total bilirubin, fibrinogen, albumin, and lymphocytes predict postoperative survival in hepatocellular carcinoma.2023Cancer medicineFree full text
  70. M2 macrophage-secreted exosomes promote metastasis and increase vascular permeability in hepatocellular carcinoma.2023Cell communication and signaling : CCSFree full text
  71. Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent manners.2023Cell metabolism
  72. Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery.2023Clinical and translational medicineFree full text
  73. Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network.2023Genome medicineFree full text
  74. Copper transporter gene ATP7A: A predictive biomarker for immunotherapy and targeted therapy in hepatocellular carcinoma.2023International immunopharmacology
  75. Multiple sclerosing hemangiomas mimicking hepatocellular carcinoma: A case report.2023International journal of immunopathology and pharmacologyFree full text
  76. Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma.2023Journal for immunotherapy of cancerFree full text
  77. GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway.2023Journal for immunotherapy of cancerFree full text
  78. The Prognostic and Therapeutic Role of Histone Acetylation Modification in LIHC Development and Progression.2023Medicina (Kaunas, Lithuania)Free full text
  79. The Diagnostic and Prognostic Value of miR-155 in Cancers: An Updated Meta-analysis.2023Molecular diagnosis & therapy
  80. Stroma-associated FSTL3 is a factor of calcium channel-derived tumor fibrosis.2023Scientific reportsFree full text
  81. Long noncoding RNA 02027 inhibits proliferation, migration and invasion of hepatocellular carcinoma via miR-625-3p/PDLIM5 pathway.2023The journal of gene medicine
  82. Radiomics analysis of pretreatment MRI in predicting tumor response and outcome in hepatocellular carcinoma with transarterial chemoembolization: a two-center collaborative study.2022Abdominal radiology (New York)
  83. Preoperative application of systemic inflammatory biomarkers combined with MR imaging features in predicting microvascular invasion of hepatocellular carcinoma.2022Abdominal radiology (New York)
  84. An immune subtype-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing analysis.2022AgingFree full text
  85. Low Psoas-Muscle index is associated with decreased survival in hepatocellular carcinoma treated with transarterial chemoembolization.2022Annals of medicineFree full text
  86. Transcatheter arterial chemoembolization alone versus combined with microwave ablation for recurrent small hepatocellular carcinoma after resection: a retrospective comparative study.2022BMC gastroenterologyFree full text
  87. Cancer-associated fibroblast exosomes promote chemoresistance to cisplatin in hepatocellular carcinoma through circZFR targeting signal transducers and activators of transcription (STAT3)/ nuclear factor -kappa B (NF-κB) pathway.2022BioengineeredFree full text
  88. An overview: Management of patients with advanced hepatocellular carcinoma.2022Bioscience trends
  89. Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center.2022Canadian journal of gastroenterology & hepatologyFree full text
  90. ARID1A Is a Prognostic Biomarker and Associated with Immune Infiltrates in Hepatocellular Carcinoma.2022Canadian journal of gastroenterology & hepatologyFree full text
  91. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells.2022Cell reports
  92. Heat shock protein A12A activates migration of hepatocellular carcinoma cells in a monocarboxylate transporter 4-dependent manner.2022Cell stress & chaperonesFree full text
  93. VLCAD inhibits the proliferation and invasion of hepatocellular cancer cells through regulating PI3K/AKT axis.2022Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  94. Identification of Biomarkers Associated with Hepatocellular Carcinoma Stem Cell Characteristics Based on Co-Expression Network Analysis of Transcriptome Data and Stemness Index.2022Critical reviews in eukaryotic gene expression
  95. DCE-MRI based radiomics nomogram for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma.2022European radiology
  96. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.2022Frontiers in immunologyFree full text
  97. Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy.2022Frontiers in immunologyFree full text
  98. Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  99. Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.2022Journal for immunotherapy of cancerFree full text
  100. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.2022Journal for immunotherapy of cancerFree full text
  101. CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.2022Journal of experimental & clinical cancer research : CRFree full text
  102. The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy.2022Journal of hepatology
  103. TED: Two-stage expert-guided interpretable diagnosis framework for microvascular invasion in hepatocellular carcinoma.2022Medical image analysis
  104. LiSNet: An artificial intelligence -based tool for liver imaging staging of hepatocellular carcinoma aggressiveness.2022Medical physics
  105. Expression profile and prognostic values of SMC family members in HCC.2022MedicineFree full text
  106. PRDM1/BLIMP1 induces cancer immune evasion by modulating the USP22-SPI1-PD-L1 axis in hepatocellular carcinoma cells.2022Nature communicationsFree full text
  107. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.2022Redox biologyFree full text
  108. A gene signature is critical for intrahepatic cholangiocarcinoma stem cell self-renewal and chemotherapeutic response.2022Stem cell research & therapyFree full text
  109. LINC01291 promotes hepatocellular carcinoma development by targeting the miR-186-5p/OXSR1 axis.2022The journal of gene medicine
  110. The "Six-and-Twelve" Score for Recurrent HCC Patients Receiving TACE: Does it Still Work?2021Cardiovascular and interventional radiology
  111. Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma.2021Experimental cell research
  112. Roles of circular RNAs in the progression of hepatocellular carcinoma and their values as diagnostic and prognostic biomarkers.2021Gene
  113. circCORO1C promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing the expression of PD-L1 through NF-κB pathway.2021Journal of clinical laboratory analysisFree full text
  114. Evaluating the predictive power of circulating tumor cells for the prognosis of transarterial chemoembolization treatment on patients with advanced hepatocellular carcinoma.2021MedicineFree full text
  115. HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation.2021Signal transduction and targeted therapyFree full text
  116. Development and Validation of a RNA Binding Protein-Associated Prognostic Model for Hepatocellular Carcinoma.2021Technology in cancer research & treatmentFree full text
  117. Clinicopathological and Prognostic Significance of Klotho and Estrogen Receptors Expression in Human Hepatocellular Carcinoma.2021The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
Chinese-language papers (not in the count)6
  1. [Novel research horizon for liver transplantation management model in hepatocellular carcinoma based on the tumor-donor liver-recipient].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Analysis of clinical efficacy and perioperative treatment strategies after radical resection for hepatocellular carcinoma with major vascular invasion and tumor thrombus].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  3. [Status and challenges of neoadjuvant immunotherapy for hepatocellular carcinoma].2023Zhonghua wai ke za zhi [Chinese journal of surgery]
  4. [Efficacy and safety of neoadjuvant immunotherapy for hepatocellular carcinoma].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  5. [Surgical treatment of primary liver cancer:a report of 10 966 cases].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
  6. [Clinical efficacy and prognostic factors analysis following curative hepatectomy for hepatocellular carcinoma patients with different China Liver Cancer Staging].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status21
  1. Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After SurgeryRecruitingNCT06762782Lead sponsorPhase 2Start 2025-02
  2. A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingNCT07131501Lead sponsorPhase 2Start 2025-08
  3. Immunotherapy for Hepatocellular CarcinomaRecruitingNCT06241326Lead sponsorStart 2024-03
  4. Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular CarcinomaRecruitingNCT05613478Lead sponsorPhase 3Start 2023-01
  5. Goal-directed LCVP Based on HP in Laparoscopic HepatectomyRecruitingNCT05887661Lead sponsorN/AStart 2022-05
  6. The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACECompletedNCT06041425Lead sponsorPhase 4Start 2023-08
  7. Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver TransplantationStatus unknownNCT05355155Lead sponsorPhase 2Start 2022-05
  8. Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04052152Lead sponsorPhase 2Start 2019-06
  9. SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular CarcinomaStatus unknownNCT04297202Lead sponsorPhase 2Start 2019-12
  10. Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCCStatus unknownNCT02338297Lead (inferred)Phase 3Start 2016-02
  11. Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular CarcinomaNot yet recruitingNCT07866612Study siteN/AStart 2026-12
  12. MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)RecruitingNCT07479485Study sitePhase 1/Phase 2Start 2026-04
  13. β-alanine in the Treatment of Advanced Hepatocellular CarcinomaRecruitingNCT07317414Study sitePhase 2Start 2025-12
  14. ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 OverexpressionRecruitingNCT07327034Study sitePhase 2Start 2025-06
  15. Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingNCT07176650Study sitePhase 1Start 2025-11
  16. A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular CarcionmaActive, not recruitingNCT04712643Study sitePhase 3Start 2021-03
  17. A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and BevacizumabActive, not recruitingNCT04770896Study sitePhase 3Start 2021-04
  18. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  19. The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma SubjectsTerminatedNCT03236649Study sitePhase 3Start 2017-09
  20. The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma SubjectsStatus unknownNCT03236636Study sitePhase 3Start 2017-09
  21. Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) PatientsStatus unknownNCT02956772Study sitePhase 2Start 2016-11

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 199 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 2.0%.

Papers led
199
2021–2025
Trials led
31
any status, ClinicalTrials.gov
Open trials led
23
recruiting or about to
Open trials as a site
6
led by another institution
Papers led per year
2021: 282820212022: 393920222023: 434320232024: 434320242025: 41412025

8 hospitals in Nanjing for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 29

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic Gastrectomy
    Phase
    N/A
    Started
    2026-01
    Registry
    NCT07351474

    Age 65 years to 100 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  2. Recruiting
    SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2026-04
    Registry
    NCT07464756

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  3. Recruiting
    Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
    Phase
    Phase 2
    Started
    2026-03
    Registry
    NCT07474324

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  4. Recruiting
    68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor Diagnosis
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07914764

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  5. Recruiting
    AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT
    Phase
    Not given
    Started
    2025-08
    Registry
    NCT07250347

    Age 18 years to 85 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  6. Recruiting
    A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
    Phase
    Phase 2
    Started
    2025-10
    Registry
    NCT07263386

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  7. Recruiting
    Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07277439

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  8. Recruiting
    Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
    Phase
    Phase 2
    Started
    2024-04
    Registry
    NCT06341595

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  9. Recruiting
    Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06461910

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  10. Recruiting
    A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2024-08
    Registry
    NCT06555471

    Age 75 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  11. Recruiting
    Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy
    Phase
    Phase 2
    Started
    2024-11
    Registry
    NCT06895447

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  12. Recruiting
    Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy
    Phase
    N/A
    Started
    2024-11
    Registry
    NCT07056010

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  13. Recruiting
    XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma
    Phase
    Phase 2
    Started
    2022-03
    Registry
    NCT05494060

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  14. Recruiting
    Multi-parametric MRI and Dual-energy CT in Patients of Gastric Cancer
    Phase
    Not given
    Started
    2021-11
    Registry
    NCT05508126

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  15. Not yet recruiting
    QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07315035

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  16. Not yet recruiting
    Robotic vs Laparoscopic Gastrectomy for cT4a Gastric Cancer
    Phase
    Phase 3
    Started
    2026-02
    Registry
    NCT07331454

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  17. Not yet recruiting
    Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOX
    Phase
    Phase 2
    Started
    2026-02
    Registry
    NCT07391826

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  18. Not yet recruiting
    A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07669740

    Age 15 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  19. Not yet recruiting
    ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
    Phase
    Not given
    Started
    2026-09
    Registry
    NCT07799649

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  20. Not yet recruiting
    Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
    Phase
    Not given
    Started
    2026-10
    Registry
    NCT07902596

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 6 listed hospitals as study sitesNanjing, Qingdao, Shanghai, Shijiazhuang, Suzhou

  21. Not yet recruiting
    D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric Cancer
    Phase
    Phase 2
    Started
    2026-11
    Registry
    NCT07912606

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  22. Not yet recruiting
    Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial
    Phase
    Phase 2
    Started
    2025-09
    Registry
    NCT07050524

    Age 18 years to 80 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  23. Not yet recruiting
    The Safe Study of Routine Closure of Mesenteric Defects Versus Non-closure After Radical Gastrectomy
    Phase
    N/A
    Started
    2022-04
    Registry
    NCT05356156

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  24. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 62 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  25. Recruiting
    Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
    Phase
    Phase 3
    Started
    2026-12
    Registry
    NCT07789184

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 25 listed hospitals as study sitesBeijing, Changchun, Chongqing, Dalian, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an

  26. Recruiting
    SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
    Phase
    Phase 1
    Started
    2025-02
    Registry
    NCT06873659

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Guangzhou, Hangzhou, Jinan, Lanzhou, Nanjing, Shanghai, Xi'an

  27. Recruiting
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
    Phase
    Phase 1/Phase 2
    Started
    2024-06
    Registry
    NCT06324357

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou

  28. Recruiting
    A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
    Phase
    Phase 3
    Started
    2024-11
    Registry
    NCT06532006

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 34 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lanzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Xiamen, Xuzhou, Yinchuan, Zhengzhou

  29. Recruiting
    The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
    Phase
    N/A
    Started
    2023-12
    Registry
    NCT06081647

    Age 18 years to 60 years (registered criteria)

    Led by Renji Hospital; 7 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Nanjing, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImaging & AIEarly detection & endoscopy
Departments in papersSurgery (general/hepatobiliary/pancreatic)Medical oncologyGastroenterology / hepatologyRadiology / nuclear medicine
Papers it led199
  1. Preoperative prediction of microsatellite instability in gastric cancer using quantitative multiparametric MRI with DCE-MRI and DWI.2026Abdominal radiology (New York)
  2. Apatinib triggers ferroptosis in gastric cancer via HDAC1/HIF1α/CA9 signaling axis.2026Anti-cancer drugs
  3. Development and validation of a cuproptosis-related gene signature for predicting prognosis and drug sensitivity in gastric cancer.2026Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  4. A functional NKILA variant (rs2273534) drives genetic susceptibility and oncogenic progression in gastric cancer via the miR-4424/OAS2 pathway.2026Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  5. ALKBH5 promotes gastric cancer angiogenesis by stabilizing LncRNA PVT1 and VEGFA RNAs via m6A demethylation.2026Molecular and cellular biochemistry
  6. Impact of Nutritional Support Under Comprehensive Nursing on Gastrointestinal Function in Patients With Gastroparesis Syndrome Following Radical Gastrectomy for Gastric Cancer.2025Annali italiani di chirurgia
  7. Advanced Multiparametric MRI Strategies for Tumor Restaging After Neoadjuvant Therapy in Locally Advanced Gastric Cancer.2025Annals of surgical oncology
  8. PLAGL2-STAU1-NCOA4 axis enhances gastric cancer peritoneal metastasis by resisting ferroptosis via ferritinophagy.2025Apoptosis : an international journal on programmed cell death
  9. Endoscopic submucosal dissection: a safe alternative to surgical intervention for young patients under 45 years of age with early gastric cancer. ESD vs. surgery in young EGC patients.2025BMC cancerFree full text
  10. Efficacy and safety of anti-PD-1 antibodies plus small molecule anti-angiogenic drugs and chemotherapy in gastric cancer peritoneal metastasis: a multicenter real-world study.2025BMC cancerFree full text
  11. Helicobacter pylori is associated with less tumor-infiltrating lymphocytes and a poor prognosis in gastric cancer.2025BMC gastroenterologyFree full text
  12. Oral microbial profile polymorphisms predict early Siewert II adenocarcinoma of esophagogastric junction.2025BMC microbiologyFree full text
  13. Laparoscopic versus open resection for unfavorable sites gastric gastrointestinal stromal tumors: a propensity weighted cohort study.2025BMC surgeryFree full text
  14. Efficacy and safety of HIPEC combined with PD-1 and SOX chemotherapy for gastric or oesophagogastric junctional cancer with peritoneal metastasis (HISTORIA): protocol for a prospective, multicentre, single-arm, phase II study.2025BMJ openFree full text
  15. Global, Regional and National Burden of Stomach Cancer and Its Prediction in 25 Years: A Cross-Sectional Study of the Global Burden of Disease Study 2021.2025British journal of hospital medicine (London, England : 2005)
  16. CEACAM6 facilitates gastric cancer progression through upregulating SLC27A2.2025Cancer gene therapy
  17. The profiles of immunosuppressive microenvironment in the Lauren intestinal-type gastric adenocarcinoma.2025Cancer immunology, immunotherapy : CIIFree full text
  18. Machine Learning-Based Prognostic Model for Gastric Cancer Using Integrated Multi-Omics Data.2025Cancer investigation
  19. Advances in the Study of Metabolic Reprogramming in Gastric Cancer.2025Cancer medicineFree full text
  20. Exosomal PKM2: A Noninvasive Diagnostic Marker Linking Macrophage Metabolic Reprogramming to Gastric Cancer Pathogenesis.2025Cancer scienceFree full text
  21. Single-cell eQTL mapping reveals cell-type-specific genes associated with the risk of gastric cancer.2025Cell genomicsFree full text
  22. Integrated network pharmacology, bioinformatics, and experiment analysis to decipher the molecular mechanism of Salidroside on Gastric cancer via targeting NCOA4-mediated ferritinophagy.2025Chemico-biological interactions
  23. Machine learning-based CT radiomics approach for predicting occult peritoneal metastasis in advanced gastric cancer preoperatively.2025Clinical radiology
  24. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis.2025Clinics and research in hepatology and gastroenterology
  25. ROS-responsive oridonin and dihydroartemisinin hetero-polymeric prodrug NPs for potentiating ferroptosis in gastric cancer by disrupting redox balance.2025Colloids and surfaces. B, Biointerfaces
  26. Biomimetic nanocrystals co-deliver paclitaxel and small-molecule LF3 for ferroptosis-combined chemotherapy for gastric cancer.2025Colloids and surfaces. B, Biointerfaces
  27. Exo-miR-1911-5p regulates ferroptosis to promote macrophages M2 polarization-mediated gastric cancer cisplatin resistance via MYB/AKR1B10/ACC.2025Communications biologyFree full text
  28. Multi-orientation and prone-position ZOOMit diffusion-weighted imaging for predicting T stage in distal gastric cancer.2025European radiology
  29. Development of machine learning models for predicting postoperative hyperglycemia in non-diabetic gastric cancer patients: a retrospective cohort study analysis.2025Frontiers in endocrinologyFree full text
  30. The impact of ADAMTS14 genetic polymorphisms and its function on susceptibility to and prognosis of gastric cancer in a Chinese Han population.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  31. Electroacupuncture Reduces Duration of Postoperative Ileus After Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Randomized Trial.2025GastroenterologyRCT
  32. Helicobacter Pylori-induced BRD2 m6A modification sensitizes gastric cancer cells to chemotherapy by breaking FLIP/Caspase-8 homeostasis.2025International journal of biological sciencesFree full text
  33. Burden and Future Trends of Gastric Cancer in 5 East Asian Countries From 1990 to 2036: Epidemiological Study Analysis Using the Global Burden of Diseases Study 2021.2025JMIR cancerFree full text
  34. A Machine Learning Model Based on Clinical Factors to Predict the Efficacy of First-Line Immunochemotherapy for Patients With Advanced Gastric Cancer: Retrospective Study.2025JMIR medical informaticsFree full text
  35. CD146+ CAFs mediate immunosuppression in gastric cancer via COL4A1: potential therapeutic targets.2025Journal for immunotherapy of cancerFree full text
  36. Dehydrocostus lactone suppresses gastric cancer progression by targeting ACLY to inhibit fatty acid synthesis and autophagic flux.2025Journal of advanced researchFree full text
  37. Qizhu Jianwei decoction triggers ferroptosis by exosome-mediated miR-199-3p/ACSL4 signaling pathways.2025Journal of ethnopharmacology
  38. SENP1 drives glycolysis and cisplatin resistance in gastric cancer via desumoylating ENO1.2025Journal of experimental & clinical cancer research : CRFree full text
  39. GC-derived exosomal circMAN1A2 promotes cancer progression and suppresses T-cell antitumour immunity by inhibiting FBXW11-mediated SFPQ degradation.2025Journal of experimental & clinical cancer research : CRFree full text
  40. TRAF6 Exerts Tumor-Promoting Effects via Genetic and Autophagic Modulation in Gastric Cancer.2025Molecular carcinogenesis
  41. YBX1 promotes 5-Fluorouracil resistance in gastric cancer via m5C-dependent ATG9A mRNA stabilization through autophagy.2025Oncogene
  42. Yiqi Huayu Jiedu decoction enhances pathological response in neoadjuvant chemotherapy-treated gastric cancer patients: A prospective, randomized controlled trial.2025Phytomedicine : international journal of phytotherapy and phytopharmacologyRCT
  43. Dysregulated lipids homeostasis disrupts CHAC1-mediated ferroptosis driving fibroblast growth factor receptor tyrosine kinase inhibitor AZD4547 resistance in gastric cancer.2025Redox biologyFree full text
  44. Blood metal levels predict digestive tract cancer risk using machine learning in a U.S. cohort.2025Scientific reportsFree full text
  45. Surgical outcomes and long-term survival of laparoscopic distal gastrectomy at high-volume centers in Korea and China: a two-centered retrospective analysis.2025Surgery todayFree full text
  46. Association of hepatitis B virus infection and helicobacter pylori co-infection with gastric disorders and cancer.2025The American journal of the medical sciences
  47. Deep learning-accelerated T2WI: image quality, efficiency, and staging performance against BLADE T2WI for gastric cancer.2024Abdominal radiology (New York)
  48. Dual-energy CT quantitative parameters to evaluate occult peritoneal metastasis in advanced gastric cancer preoperatively.2024Abdominal radiology (New York)
  49. O-GlcNAcylation-related genes mediate tumor microenvironment characteristics and prediction of immunotherapy response in gastric cancer.2024Acta biochimica et biophysica SinicaFree full text
  50. Differential diagnosis of gastric low- and high grade dysplasia using C6orf15 protein.2024Annals of diagnostic pathology
  51. Nomogram predicting survival of patients with liver metastasis from gastric signet ring-cell carcinoma: A SEER-Based population study.2024Asian journal of surgery
  52. Multimodal management of foregut neuroendocrine neoplasms.2024Best practice & research. Clinical gastroenterology
  53. Tumour cell-derived serglycin promotes IL-8 secretion of CAFs in gastric cancer.2024British journal of cancerFree full text
  54. Construct dysregulated miRNA-mRNA interaction networks to conjecture possible pathogenesis for Stomach adenocarcinomas.2024Cancer biomarkers : section A of Disease markersFree full text
  55. Leptin-mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer.2024Cancer communications (London, England)Free full text
  56. TRIM29 promotes antitumor immunity through enhancing IGF2BP1 ubiquitination and subsequent PD-L1 downregulation in gastric cancer.2024Cancer letters
  57. circVAPA-rich small extracellular vesicles derived from gastric cancer promote neural invasion by inhibiting SLIT2 expression in neuronal cells.2024Cancer letters
  58. Gastroblastoma with an ACTB-GLI1 gene fusion in a 39-year-old man.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  59. CBX4 counteracts cellular senescence to desensitize gastric cancer cells to chemotherapy by inducing YAP1 SUMOylation.2024Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  60. Comments on "No-touch endoscopic full-thickness resection technique for gastric gastrointestinal stromal tumors".2024Endoscopy
  61. A latent profile analysis of psychological resilience in gastric cancer survivors: A cross-sectional study.2024European journal of oncology nursing : the official journal of European Oncology Nursing Society
  62. Comprehensive analysis of lactylation-related gene sets and mitochondrial functions in gastric adenocarcinoma: implications for prognosis and therapeutic strategies.2024Frontiers in immunologyFree full text
  63. N6-methyladenosine-modified MIB1 promotes stemness properties and peritoneal metastasis of gastric cancer cells by ubiquitinating DDX3X.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  64. New endoscopic closure technique, "internal traction-assisted suspended closure," for GI defect closure: a pilot study (with video).2024Gastrointestinal endoscopy
  65. Circular RNA Circ_0000119 promotes gastric cancer progression via circ_0000119/miR-502-5p/MTBP axis.2024Gene
  66. Neoadjuvant chemotherapy is linked to an amended anti-tumorigenic microenvironment in gastric cancer.2024International immunopharmacology
  67. Unveiling the oncogenic role of CLDN11-secreting fibroblasts in gastric cancer peritoneal metastasis through single-cell sequencing and experimental approaches.2024International immunopharmacology
  68. Helicobacter pylori promotes gastric cancer through CagA-mediated mitochondrial cholesterol accumulation by targeting CYP11A1 redistribution.2024International journal of biological sciencesFree full text
  69. TRIM50 inhibits glycolysis and the malignant progression of gastric cancer by ubiquitinating PGK1.2024International journal of biological sciencesFree full text
  70. Intratumoral CXCL13+ CD160+ CD8+ T cells promote the formation of tertiary lymphoid structures to enhance the efficacy of immunotherapy in advanced gastric cancer.2024Journal for immunotherapy of cancerFree full text
  71. Utility of Combined Use of Imaging Features From Abdominopelvic CT and CA 125 to Identify Presence of CT Occult Peritoneal Metastases in Advanced Gastric Cancer.2024Journal of computer assisted tomography
  72. Tumor-associated macrophage-derived exosomal miR-513b-5p is a target of jianpi yangzheng decoction for inhibiting gastric cancer.2024Journal of ethnopharmacology
  73. Multidisciplinary treatment of synchronous primary advanced gastric adenocarcinoma and esophageal squamous cell carcinoma-a retrospective single-institution study.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  74. LightGBM is an Effective Predictive Model for Postoperative Complications in Gastric Cancer: A Study Integrating Radiomics with Ensemble Learning.2024Journal of imaging informatics in medicineFree full text
  75. The expansion of MDSCs induced by exosomal PD-L1 promotes the progression of gastric cancer.2024Journal of translational medicineFree full text
  76. IFIT1 + neutrophil is a causative factor of immunosuppressive features of poorly cohesive carcinoma (PCC).2024Journal of translational medicineFree full text
  77. PLA2G4A and ACHE modulate lipid profiles via glycerophospholipid metabolism in platinum-resistant gastric cancer.2024Journal of translational medicineFree full text
  78. Construction of a TAN-associated risk score model with integrated multi-omics data analysis and clinical validation in gastric cancer.2024Life sciences
  79. The role of 1400 plasma metabolites in gastric cancer: A bidirectional Mendelian randomization study and metabolic pathway analysis.2024MedicineFree full text
  80. Fat mass and obesity-associated protein (FTO) mediated m6A modification of circFAM192A promoted gastric cancer proliferation by suppressing SLC7A5 decay.2024Molecular biomedicineFree full text
  81. Molecular SPECT/CT Profiling of Claudin18.2 Expression In Vivo: Implication for Patients with Gastric Cancer.2024Molecular pharmaceutics
  82. Gut microbiota-driven metabolic alterations reveal the distinct pathogenicity of chemotherapy-induced cachexia in gastric cancer.2024Pharmacological research
  83. Nobiletin targets SREBP1/ACLY to induce autophagy-dependent cell death of gastric cancer cells through PI3K/Akt/mTOR signaling pathway.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  84. Gut microbiota-dependent modulation of pre-metastatic niches by Jianpi Yangzheng decoction in the prevention of lung metastasis of gastric cancer.2024Phytomedicine : international journal of phytotherapy and phytopharmacology
  85. MRI versus Dual-Energy CT in Local-Regional Staging of Gastric Cancer.2024Radiology
  86. Integrated analysis to identify biological features and molecular markers of poorly cohesive gastric carcinoma (PCC).2024Scientific reportsFree full text
  87. Plasma circulating tumor DNA unveils the efficacy of PD-1 inhibitors and chemotherapy in advanced gastric cancer.2024Scientific reportsFree full text
  88. First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.2024Signal transduction and targeted therapyFree full text
  89. Small Extracellular Vesicles Derived from Helicobacter Pylori-Infected Gastric Cancer Cells Induce Lymphangiogenesis and Lymphatic Remodeling via Transfer of miR-1246.2024Small (Weinheim an der Bergstrasse, Germany)
  90. Polymorphism rs1057147 located in mesothelin gene predicts lymph node metastasis in patients with gastric cancer.2023Applied microbiology and biotechnology
  91. Rs15285, a functional polymorphism located in lipoprotein lipase, predicts the risk and prognosis of gastric cancer.2023Applied microbiology and biotechnology
  92. CYP19A1 promotes gastric cancer as part of a lipid metabolism-related gene signature related to the response of immunotherapy and prognosis.2023BMC medical genomicsFree full text
  93. Cytosolic TGM2 promotes malignant progression in gastric cancer by suppressing the TRIM21-mediated ubiquitination/degradation of STAT1 in a GTP binding-dependent modality.2023Cancer communications (London, England)Free full text
  94. N6-methyladenosine modification of CENPF mRNA facilitates gastric cancer metastasis via regulating FAK nuclear export.2023Cancer communications (London, England)Free full text
  95. HKDC1 reprograms lipid metabolism to enhance gastric cancer metastasis and cisplatin resistance via forming a ribonucleoprotein complex.2023Cancer letters
  96. MSC-NPRA loop drives fatty acid oxidation to promote stemness and chemoresistance of gastric cancer.2023Cancer letters
  97. N6-methyadenosine modified SUV39H2 regulates homologous recombination through epigenetic repression of DUSP6 in gastric cancer.2023Cancer letters
  98. Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population.2023Cancer medicineFree full text
  99. ACLY promotes gastric tumorigenesis and accelerates peritoneal metastasis of gastric cancer regulated by HIF-1A.2023Cell cycle (Georgetown, Tex.)Free full text
  100. m5C-methylated lncRNA NR_033928 promotes gastric cancer proliferation by stabilizing GLS mRNA to promote glutamine metabolism reprogramming.2023Cell death & diseaseFree full text
  101. Long noncoding RNA DIAPH2-AS1 promotes neural invasion of gastric cancer via stabilizing NSUN2 to enhance the m5C modification of NTN1.2023Cell death & diseaseFree full text
  102. H19 recruited N 6 -methyladenosine (m 6 A) reader YTHDF1 to promote SCARB1 translation and facilitate angiogenesis in gastric cancer.2023Chinese medical journalFree full text
  103. Correlation analysis of lipid metabolism genes with the immune microenvironment in gastric cancer and the construction of a novel gene signature.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  104. A novel metabolism-related prognostic gene development and validation in gastric cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  105. LINC00659 cooperated with ALKBH5 to accelerate gastric cancer progression by stabilising JAK1 mRNA in an m6 A-YTHDF2-dependent manner.2023Clinical and translational medicineFree full text
  106. CircRPPH1 promotes the stemness of gastric cancer cells by targeting miR-375/SLC7A11 axis.2023Environmental toxicology
  107. Metabolic reprogramming involves in transition of activated/resting CD4+ memory T cells and prognosis of gastric cancer.2023Frontiers in immunologyFree full text
  108. Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis.2023Frontiers in immunologyFree full text
  109. LOC101929709 promotes gastric cancer progression by aiding LIN28B to stabilize c-MYC mRNA.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  110. An Unusual Cause of Gastric Masses.2023Gastroenterology
  111. Advanced gastric adenocarcinoma misdiagnosed as gastric stromal tumor.2023Gastrointestinal endoscopy
  112. A Prediction Model Based on the Risk Factors Associated with Pathological Upgrading in Patients with Early-Stage Gastric Neoplasms Diagnosed by Endoscopic Forceps Biopsy.2023Gut and liverFree full text
  113. DZIP1 expressed in fibroblasts and tumor cells may affect immunosuppression and metastatic potential in gastric cancer.2023International immunopharmacology
  114. Neutrophils promote tumor invasion via FAM3C-mediated epithelial-to-mesenchymal transition in gastric cancer.2023International journal of biological sciencesFree full text
  115. Prognostic Value of Tumor Size in Gastric Cancer: A Retrospective Cohort Study Based on SEER Database.2023International journal of surgical pathology
  116. Adverse outcomes and health-ecological influencing factors of preoperative frailty among elderly patients with gastric cancer.2023Journal of cancer research and clinical oncologyFree full text
  117. Jianpi Yangzheng decoction suppresses gastric cancer progression via modulating the miR-448/CLDN18.2 mediated YAP/TAZ signaling.2023Journal of ethnopharmacology
  118. Gastric cancer-derived LBP promotes liver metastasis by driving intrahepatic fibrotic pre-metastatic niche formation.2023Journal of experimental & clinical cancer research : CRFree full text
  119. SEC23A confers ER stress resistance in gastric cancer by forming the ER stress-SEC23A-autophagy negative feedback loop.2023Journal of experimental & clinical cancer research : CRFree full text
  120. Neural Invasion is an Independent Prognostic Factor in Young and Lymph Node Negative Gastric Cancer Patients Underwent Curative Gastrectomy.2023Journal of investigative surgery : the official journal of the Academy of Surgical Research
  121. Loss of miR-26b-5p promotes gastric cancer progression via miR-26b-5p-PDE4B/CDK8-STAT3 feedback loop.2023Journal of translational medicineFree full text
  122. Diallyl trisulfide inhibits gastric cancer stem cell properties through ΔNp63/sonic hedgehog pathway.2023Molecular carcinogenesis
  123. Directional conjugation of Trop2 antibody to black phosphorus nanosheets for phototherapy in orthotopic gastric carcinoma.2023Nanomedicine : nanotechnology, biology, and medicine
  124. Peritoneal high-fat environment promotes peritoneal metastasis of gastric cancer cells through activation of NSUN2-mediated ORAI2 m5C modification.2023Oncogene
  125. USP51/ZEB1/ACTA2 axis promotes mesenchymal phenotype in gastric cancer and is associated with low cohesion characteristics.2023Pharmacological research
  126. Nobiletin inhibits de novo FA synthesis to alleviate gastric cancer progression by regulating endoplasmic reticulum stress.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  127. Effectiveness of preserved vagal nerve in totally laparoscopy radical distal gastrectomy: a matched-paired cohort analysis.2023Surgical endoscopy
  128. To cut or not to cut? A prospective randomized controlled trial on short-term outcomes of the uncut Roux-en-Y reconstruction for gastric cancer.2023Surgical endoscopyFree full text
  129. Dexmedetomidine promotes ferroptotic cell death in gastric cancer via hsa_circ_0008035/miR-302a/E2F7 axis.2023The Kaohsiung journal of medical sciencesFree full text
  130. Individualized Endoscopic Surveillance for Metachronous Gastric Cancer After Endoscopic Submucosal Dissection: A Retrospective Observational Study.2023The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  131. Long non-coding RNA LGALS8-AS1 facilitates PLAGL2-mediated malignant phenotypes in gastric cancer.2023The journal of gene medicine
  132. Prediction of lymph node metastasis in early gastric signet-ring cell carcinoma: A real-world retrospective cohort study.2023World journal of gastroenterologyFree full text
  133. Prognostic aspects of lymphovascular invasion in localized gastric cancer: new insights into the radiomics and deep transfer learning from contrast-enhanced CT imaging.2022Abdominal radiology (New York)
  134. Succinylation Inhibits the Enzymatic Hydrolysis of the Extracellular Matrix Protein Fibrillin 1 and Promotes Gastric Cancer Progression.2022Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  135. Stress and autonomic nerve dysfunction monitoring in perioperative gastric cancer patients using a smart device.2022Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, IncFree full text
  136. Polymorphisms of an oncogenic gene, mesothelin, predict the risk and prognosis of gastric cancer in a Chinese Han population.2022Archives of toxicology
  137. Proximal gastrectomy may be a reasonable choice for patients with selected proximal advanced gastric cancer: A propensity score-matched analysis.2022Asian journal of surgery
  138. Integrated Analyses of m6A Regulator-Based Signature on Its Clinical Application and Immunogenomic Landscape in Stomach Adenocarcinoma.2022BioMed research internationalFree full text
  139. The Long-Term Outcomes of Surgery Versus Endoscopic Treatment in Patients With Siewert Type II T1M0N0 Adenocarcinoma of the Esophagogastric Junction.2022Cancer control : journal of the Moffitt Cancer CenterFree full text
  140. Tumor-derived IL-8 facilitates lymph node metastasis of gastric cancer via PD-1 up-regulation in CD8+ T cells.2022Cancer immunology, immunotherapy : CIIFree full text
  141. Plasma thioredoxin reductase: a potential diagnostic biomarker for gastric cancer.2022Carcinogenesis
  142. CircTHBS1 drives gastric cancer progression by increasing INHBA mRNA expression and stability in a ceRNA- and RBP-dependent manner.2022Cell death & diseaseFree full text
  143. Exosomal circRELL1 serves as a miR-637 sponge to modulate gastric cancer progression via regulating autophagy activation.2022Cell death & diseaseFree full text
  144. Exosome-transmitted miR-769-5p confers cisplatin resistance and progression in gastric cancer by targeting CASP9 and promoting the ubiquitination degradation of p53.2022Clinical and translational medicineFree full text
  145. Circular CPM promotes chemoresistance of gastric cancer via activating PRKAA2-mediated autophagy.2022Clinical and translational medicineFree full text
  146. Diagnostic, Prognostic, and Immunological Roles of FABP4 in Pancancer: A Bioinformatics Analysis.2022Computational and mathematical methods in medicineFree full text
  147. Author's reply: A true fundic gland polyp in Meckel's diverticulum.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  148. A fundic gland polyp and peptic ulcer in Meckel's diverticulum.2022Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  149. LncRNA H19 Promoted the Epithelial to Mesenchymal Transition and Metastasis in Gastric Cancer via Activating Wnt/β-Catenin Signaling.2022Digestive diseases (Basel, Switzerland)
  150. Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors.2022Drugs of today (Barcelona, Spain : 1998)
  151. The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.2022European journal of medical researchFree full text
  152. Nomogram for preoperative estimation of histologic grade in gastrointestinal neuroendocrine tumors.2022Frontiers in endocrinologyFree full text
  153. SP1-Induced Upregulation of lncRNA LINC00659 Promotes Tumour Progression in Gastric Cancer by Regulating miR-370/AQP3 Axis.2022Frontiers in endocrinologyFree full text
  154. Multi‑institutional development and validation of a nomogram to predict prognosis of early-onset gastric cancer patients.2022Frontiers in immunologyFree full text
  155. Cancer-associated fibroblasts-derived HAPLN1 promotes tumour invasion through extracellular matrix remodeling in gastric cancer.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  156. Risk factors for the failure of endoscopic resection of gastric submucosal tumors: a long-term retrospective case-control study.2022Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  157. Induction of Fibroblast Growth Factor Receptor 4 by Helicobacter pylori via Signal Transducer and Activator of Transcription 3 With a Feedforward Activation Loop Involving SRC Signaling in Gastric Cancer.2022GastroenterologyFree full text
  158. Comparison of Computed Tomography Features of Gastric and Small Bowel Gastrointestinal Stromal Tumors With Different Risk Grades.2022Journal of computer assisted tomography
  159. Gastric cancer-derived exosomal miR-519a-3p promotes liver metastasis by inducing intrahepatic M2-like macrophage-mediated angiogenesis.2022Journal of experimental & clinical cancer research : CRFree full text
  160. Histopathological Characteristics and Therapeutic Outcomes of Endoscopic Submucosal Dissection for Gastric High-Grade Intraepithelial Neoplasia.2022Journal of laparoendoscopic & advanced surgical techniques. Part A
  161. Obesity promotes lipid accumulation in lymph node metastasis of gastric cancer: a retrospective case‒control study.2022Lipids in health and diseaseFree full text
  162. Case fatality rate of the adult in-patients with COVID-19 and digestive system tumors: A systematic review and meta-analysis.2022MedicineFree full text
  163. Knockdown of circ_0067934 inhibits gastric cancer cell proliferation, migration and invasion via the miR‑1301‑3p/KIF23 axis.2022Molecular medicine reportsFree full text
  164. Comparison of five sarcopenia screening tools in preoperative patients with gastric cancer using the diagnostic criteria of the European Working Group on Sarcopenia in Older People 2.2022Nutrition (Burbank, Los Angeles County, Calif.)
  165. Comprehensive Molecular Analyses of an SLC Family-Based Model in Stomach Adenocarcinoma.2022Pathology oncology research : PORFree full text
  166. Correlation of MIF-AS1 polymorphisms with the risk and prognosis of gastric cancer.2022Pathology, research and practice
  167. Effect of modified Jianpi Yangzheng on regulating content of PKM2 in gastric cancer cells-derived exosomes.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
  168. Endoscopic submucosal dissection for exploration and removal of a gastric buried foreign body.2022Revista espanola de enfermedades digestivas
  169. Endoscopic full-thickness resection of a gastric schwannoma.2022Revista espanola de enfermedades digestivas
  170. Yes-associated protein gene overexpression regulated by β-catenin promotes gastric cancer cell tumorigenesis.2022Technology and health care : official journal of the European Society for Engineering and MedicineFree full text
  171. Successful treatment of an enormous rectal mucosa-associated lymphoid tissue lymphoma by endoscopic full-thickness resection: A case report.2022World journal of gastroenterologyFree full text
  172. ARF3 inhibits proliferation and promotes apoptosis in gastric cancer by regulating AKT and ERK pathway.2021Acta biochimica Polonica
  173. STAM2 knockdown inhibits proliferation, migration, and invasion by affecting the JAK2/STAT3 signaling pathway in gastric cancer.2021Acta biochimica et biophysica Sinica
  174. Apatinib inhibits the proliferation of gastric cancer cells via the AKT/GSK signaling pathway in vivo.2021AgingFree full text
  175. New genotypes of Helicobacter Pylori VacA d-region identified from global strains.2021BMC molecular and cell biologyFree full text
  176. HER2-targeted therapies in gastric cancer.2021Biochimica et biophysica acta. Reviews on cancer
  177. Bioinformatics-based analysis of the association between the A1-chimaerin (CHN1) gene and gastric cancer.2021BioengineeredFree full text
  178. Genetic polymorphisms of Cathepsin B are associated with gastric cancer risk and prognosis in a Chinese population.2021Cancer biomarkers : section A of Disease markersFree full text
  179. Natriuretic peptide receptor a promotes gastric malignancy through angiogenesis process.2021Cell death & diseaseFree full text
  180. ELK4-mediated lncRNA SNHG22 promotes gastric cancer progression through interacting with EZH2 and regulating miR-200c-3p/Notch1 axis.2021Cell death & diseaseFree full text
  181. Circular RNA UBE2Q2 promotes malignant progression of gastric cancer by regulating signal transducer and activator of transcription 3-mediated autophagy and glycolysis.2021Cell death & diseaseFree full text
  182. Long intergenic non-coding RNA 00473 promotes proliferation and migration of gastric cancer via the miR-16-5p/CCND2 axis and by regulating AQP3.2021Cell death & diseaseFree full text
  183. A Comparison of Tumor-Associated and Non-Tumor-Associated Gastric Microbiota in Gastric Cancer Patients.2021Digestive diseases and sciences
  184. Alterations of Gastric Microbiota in Gastric Cancer and Precancerous Stages.2021Frontiers in cellular and infection microbiologyFree full text
  185. Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  186. Correlations of SNHG5 genetic polymorphisms with susceptibility and prognosis to gastric cancer in a Chinese population.2021Genomics
  187. Vicenin-2 inhibits the Helicobacterium pylori infection associated gastric carcinogenic events through modulation of PI3K/AKT and Nrf2 signaling in GES-1 cells.2021Journal of biochemical and molecular toxicology
  188. Involvement of APRIL in Helicobacter pylori-related gastric cancer.2021Journal of cancer research and clinical oncologyFree full text
  189. mRNA microarray profiling identifies a novel circulating HTRA2 for detection of gastric cancer.2021Journal of clinical laboratory analysisFree full text
  190. CircFAM73A promotes the cancer stem cell-like properties of gastric cancer through the miR-490-3p/HMGA2 positive feedback loop and HNRNPK-mediated β-catenin stabilization.2021Journal of experimental & clinical cancer research : CRFree full text
  191. Circular RNA circLMO7 acts as a microRNA-30a-3p sponge to promote gastric cancer progression via the WNT2/β-catenin pathway.2021Journal of experimental & clinical cancer research : CRFree full text
  192. Circular RNA TMEM87A promotes cell proliferation and metastasis of gastric cancer by elevating ULK1 via sponging miR-142-5p.2021Journal of gastroenterology
  193. Effectiveness of beinaglutide in a patient with late dumping syndrome after gastrectomy: A case report.2021MedicineFree full text
  194. Modulatory effect of Tagetes erecta flowers essential oils via Nrf2/HO-1/NF-κB/p65 axis mediated suppression of N-methyl-N'nitro-N-nitroguanidine (MNNG) induced gastric cancer in rats.2021Molecular and cellular biochemistry
  195. A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling.2021Molecular cancerFree full text
  196. Heritable Variants in the Chromosome 1q22 Locus Increase Gastric Cancer Risk via Altered Chromatin Looping and Increased UBAP2L Expression.2021Molecular cancer research : MCR
  197. Radical Subtotal Gastrectomy for Distal Gastric Cancer After Sleeve Gastrectomy: a Case Report.2021Obesity surgery
  198. miR-151a-3p-rich small extracellular vesicles derived from gastric cancer accelerate liver metastasis via initiating a hepatic stemness-enhancing niche.2021Oncogene
  199. Circulating tumor cells: A surrogate to predict the effect of treatment and overall survival in gastric adenocarcinoma.2021The International journal of biological markers
Chinese-language papers (not in the count)15
  1. [Effect of electroacupuncture on intestinal function after gastric cancer surgery].2025Zhongguo zhen jiu = Chinese acupuncture & moxibustionRCT
  2. [Pathological evaluation of advanced gastric cancer after neoadjuvant chemotherapy].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [Current status and prospects of surgical treatment for adenocarcinoma of the esophagogastric junction].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  4. [Feasibility and safety of laparoscopic purse-string suture clamps and multi-functional seal caps for total laparoscopic radical total gastrectomy].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [Rethinking of robotic radical gastric cancer surgery: similarities and differences to laparoscopic surgery].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  6. [Preliminary application results of laparoscopic assisted proximal gastrectomy λ-shaped double tract anastomosis].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [History of digestive tract reconstruction after gastrectomy].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Quality control of digestive tract reconstruction after proximal gastrectomy].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  9. [Diagnosis, prevention and treatment of post-operative rare complications after radical gastrectomy for gastric cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  10. [Analysis of clinicopathological characteristics of gastric-type inverted hyperplastic polyps].2022Zhonghua bing li xue za zhi = Chinese journal of pathology
  11. [A multicenter retrospective study on the efficacy of different anti-reflux reconstruction methods after proximal gastrectomy for gastric cancer].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  12. [Real-world data analysis of 3012 patients undergoing laparoscopic radical gastrectomy in a single center over the past 12 years].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  13. [Anti-reflux gastrointestinal reconstruction techniques after laparoscopic proximal gastrectomy].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  14. [Laparoscopic circular stapled gastrointestinal anastomosis using novel device of sealed cap access after total laparoscopic gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  15. [Risk factors and risk model of lymph node metastasis in early gastric cancer].2021Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
All its trials on ClinicalTrials.gov, any status50
  1. QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric CancerNot yet recruitingNCT07315035Lead sponsorPhase 2Start 2026-01
  2. 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor DiagnosisRecruitingNCT07914764Lead sponsorStart 2026-08
  3. Robotic vs Laparoscopic Gastrectomy for cT4a Gastric CancerNot yet recruitingNCT07331454Lead sponsorPhase 3Start 2026-02
  4. Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical TrialRecruitingNCT07474324Lead sponsorPhase 2Start 2026-03
  5. Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ AdenocarcinomaNot yet recruitingNCT07902596Lead sponsorStart 2026-10
  6. Megestrol Acetate Oral Suspension for Cachexia in Patients With cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Receiving Neoadjuvant Therapy With Serplulimab Combined With SOXNot yet recruitingNCT07391826Lead sponsorPhase 2Start 2026-02
  7. A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant TherapyNot yet recruitingNCT07669740Lead sponsorPhase 2Start 2026-07
  8. ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPRNot yet recruitingNCT07799649Lead sponsorStart 2026-09
  9. Remimazolam for Reducing Postoperative Delirium in Elderly Patients Undergoing Laparoscopic GastrectomyRecruitingNCT07351474Lead sponsorN/AStart 2026-01
  10. D2 Gastrectomy With or Without Para-Aortic Lymph Node Dissection After Chemoimmunotherapy for Gastric CancerNot yet recruitingNCT07912606Lead sponsorPhase 2Start 2026-11
  11. SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric CancerRecruitingNCT07464756Lead sponsorPhase 2Start 2026-04
  12. Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ AdenocarcinomaRecruitingNCT07277439Lead sponsorPhase 2Start 2025-12
  13. AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CTRecruitingNCT07250347Lead sponsorStart 2025-08
  14. A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric CancerRecruitingNCT07263386Lead sponsorPhase 2Start 2025-10
  15. Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II TrialNot yet recruitingNCT07050524Lead sponsorPhase 2Start 2025-09
  16. Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALMRecruitingNCT06341595Lead sponsorPhase 2Start 2024-04
  17. Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion ImmunochemotherapyRecruitingNCT07056010Lead sponsorN/AStart 2024-11
  18. A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric CancerRecruitingNCT06555471Lead sponsorPhase 2Start 2024-08
  19. Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant TherapyRecruitingNCT06895447Lead sponsorPhase 2Start 2024-11
  20. XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction AdenocarcinomaRecruitingNCT05494060Lead sponsorPhase 2Start 2022-03
  21. The Safe Study of Routine Closure of Mesenteric Defects Versus Non-closure After Radical GastrectomyNot yet recruitingNCT05356156Lead sponsorN/AStart 2022-04
  22. Multi-parametric MRI and Dual-energy CT in Patients of Gastric CancerRecruitingNCT05508126Lead sponsorStart 2021-11
  23. Using ctDNA to Guide Treatment Decisions for Stage III Gastric CancerActive, not recruitingNCT06939439Lead sponsorPhase 3Start 2024-12
  24. The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PMActive, not recruitingNCT06427252Lead sponsorPhase 2Start 2024-05
  25. MRI and CT in Gastroesophageal Junction or Upper Gastric AdenocarcinomaActive, not recruitingNCT06640153Lead sponsorStart 2024-08
  26. Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)CompletedNCT04963088Lead sponsorPhase 1/Phase 2Start 2021-03
  27. Clinical Study of Gastric Cancer, Colorectal Cancer and Bladder Cancer Based on Liquid BiopsyStatus unknownNCT04385316Lead sponsorStart 2019-09
  28. Uncut Roux-en-Y Gastrojejunostomy for Early Gastric Cancer PatientsStatus unknownNCT02644148Lead sponsorPhase 2Start 2016-02
  29. Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06461910Lead (inferred)Phase 2Start 2024-06
  30. Analysis of Influencing Factors of Preoperative Frailty in Elderly Patients With Gastric Cancer Based on the Health Ecology TheoryCompletedNCT04929587Lead (inferred)Start 2021-01
  31. Enteral Nutrition After PancreaticoduodenectomyCompletedNCT03150615Lead (inferred)N/AStart 2016-09
  32. Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion TherapyRecruitingNCT07789184Study sitePhase 3Start 2026-12
  33. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  34. SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid TumorsRecruitingNCT06873659Study sitePhase 1Start 2025-02
  35. A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric CancerRecruitingNCT06532006Study sitePhase 3Start 2024-11
  36. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has SpreadRecruitingNCT06324357Study sitePhase 1/Phase 2Start 2024-06
  37. The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy ProcedureRecruitingNCT06081647Study siteN/AStart 2023-12
  38. A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Study sitePhase 1Start 2024-08
  39. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  40. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  41. Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)Active, not recruitingNCT04152499Study sitePhase 1/Phase 2Start 2020-02
  42. A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT04053205Study sitePhase 1/Phase 2Start 2019-11
  43. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric CancersStatus unknownNCT03468712Study siteN/AStart 2018-03
  44. Incidence of Pancreatic Fistula After Radical GastrectomyStatus unknownNCT03391687Study siteStart 2017-12
  45. Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center StudyStatus unknownNCT03121729Study siteN/AStart 2017-06
  46. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric CancerStatus unknownNCT02845986Study sitePhase 2Start 2016-09
  47. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  48. Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Status unknownNCT02461407Study sitePhase 2/Phase 3Start 2015-06
  49. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction CancerCompletedNCT02178956Study sitePhase 3Start 2014-10
  50. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led no English-language PubMed papers on retinoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Nanjing for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)2
  1. CD24 blunts the sensitivity of retinoblastoma to vincristine by modulating autophagy.2020Molecular oncology
  2. miR-498 promotes cell proliferation and inhibits cell apoptosis in retinoblastoma by directly targeting CCPG1.2018Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Nanjing for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 4 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 1120242025: 002025

25 hospitals in Nanjing for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicinePediatrics
Papers it led4
  1. Design and bio-evaluation of novel millepachine derivatives targeting tubulin colchicine binding site for treatment of osteosarcoma.2024Bioorganic chemistry
  2. Long non-coding RNA DUXAP10 exerts oncogenic properties in osteosarcoma by recruiting HuR to enhance SOX18 mRNA stability.2022Human cell
  3. Hyaluronate-Based Self-Stabilized Nanoparticles for Immunosuppression Reversion and Immunochemotherapy in Osteosarcoma Treatment.2021ACS biomaterials science & engineering
  4. A Hypoxia Gene-Based Signature to Predict the Survival and Affect the Tumor Immune Microenvironment of Osteosarcoma in Children.2021Journal of immunology research
Chinese-language papers (not in the count)2
  1. [Ewing's sarcoma of central nervous system: a clinicopathological analysis of six cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Primary osteosarcoma of left atrium: report of a case].2021Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)21
  1. LINC00266-1/miR-548c-3p/SMAD2 feedback loop stimulates the development of osteosarcoma.2020Cell death & disease
  2. miR-210-5p promotes epithelial-mesenchymal transition by inhibiting PIK3R5 thereby activating oncogenic autophagy in osteosarcoma cells.2020Cell death & disease
  3. Performance of prognostic nomogram in predicting long-term survival outcomes for osteosarcoma.2020Journal of biological regulators and homeostatic agents
  4. Decreased long non-coding RNA lincFOXF1 indicates poor progression and promotes cell migration and metastasis in osteosarcoma.2020Journal of cellular and molecular medicine
  5. Identification of possible reductants in the aqueous leaf extract of mangrove plant Rhizophora apiculata for the fabrication and cytotoxicity of silver nanoparticles against human osteosarcoma MG-63 cells.2020Materials science & engineering. C, Materials for biological applications
  6. Overexpression of miR-1258 inhibits cell proliferation by targeting AKT3 in osteosarcoma.2019Biochemical and biophysical research communications
  7. Hsa-miR-889-3p promotes the proliferation of osteosarcoma through inhibiting myeloid cell nuclear differentiation antigen expression.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  8. LncRNA SNHG3/miRNA-151a-3p/RAB22A axis regulates invasion and migration of osteosarcoma.2019Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  9. Triple-threat activity of PEDF in bone tumors: Tumor inhibition, tissue preservation and cardioprotection against doxorubicin.2019Bone
  10. TIPE1 suppresses osteosarcoma tumor growth by regulating macrophage infiltration.2019Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  11. LncSNHG16 promotes proliferation and migration of osteosarcoma cells by targeting microRNA-146a-5p.2019European review for medical and pharmacological sciences
  12. A four serum-miRNA panel serves as a potential diagnostic biomarker of osteosarcoma.2019International journal of clinical oncology
  13. A newly synthesized oleanolic acid derivative inhibits the growth of osteosarcoma cells in vitro and in vivo by decreasing c-MYC-dependent glycolysis.2019Journal of cellular biochemistry
  14. miR-624-5p promoted tumorigenesis and metastasis by suppressing hippo signaling through targeting PTPRB in osteosarcoma cells.2019Journal of experimental & clinical cancer research : CR
  15. Identification of circulating miR-663a as a potential biomarker for diagnosing osteosarcoma.2019Pathology, research and practice
  16. FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2.2018Biochemical and biophysical research communications
  17. SLIT2/ROBO1 axis contributes to the Warburg effect in osteosarcoma through activation of SRC/ERK/c-MYC/PFKFB2 pathway.2018Cell death & disease
  18. Clinical Significance of G Protein-Coupled Receptor 110 (GPR110) as a Novel Prognostic Biomarker in Osteosarcoma.2018Medical science monitor : international medical journal of experimental and clinical research
  19. MiR-143 regulates the proliferation and migration of osteosarcoma cells through targeting MAPK7.2017Archives of biochemistry and biophysics
  20. Cullin-1 regulates MG63 cell proliferation and metastasis and is a novel prognostic marker of osteosarcoma.2017The International journal of biological markers
  21. Down-regulation of RBP-J mediated by microRNA-133a suppresses dendritic cells and functions as a potential tumor suppressor in osteosarcoma.2016Experimental cell research

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 14 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 2.7%.

Papers led
14
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 4420232024: 3320242025: 442025

11 hospitals in Nanjing for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety of Robotic Surgery for GISTs at Special Anatomic Sites
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT07405125

    Age 18 years to 75 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  2. Recruiting
    Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
    Phase
    Phase 2/Phase 3
    Started
    2026-05
    Registry
    NCT07379047

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shijiazhuang, Taiyuan, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicine
Papers it led14
  1. Laparoscopic versus open resection for unfavorable sites gastric gastrointestinal stromal tumors: a propensity weighted cohort study.2025BMC surgeryFree full text
  2. Monitoring the plasma concentration of ripretinib and its metabolites in Chinese patients with gastrointestinal stromal tumors in a real-life setting.2025Cancer
  3. Influence of genetic variants of imatinib on pharmacokinetics and recurrence-free survival in postoperative patients with gastrointestinal stromal tumor.2025European journal of clinical pharmacology
  4. Using body composition to predict treatment-related adverse events and disease-free survival in patients with gastrointestinal stromal tumors treated with imatinib: a retrospective cohort study.2025Frontiers in immunology
  5. USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition.2024Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  6. TRIM21/USP15 balances ACSL4 stability and the imatinib resistance of gastrointestinal stromal tumors.2024British journal of cancer
  7. Comments on "No-touch endoscopic full-thickness resection technique for gastric gastrointestinal stromal tumors".2024Endoscopy
  8. N6-methyladenosine-modified USP13 induces pro-survival autophagy and imatinib resistance via regulating the stabilization of autophagy-related protein 5 in gastrointestinal stromal tumors.2023Cell death and differentiation
  9. A Multimodal Multipath Artificial Intelligence System for Diagnosing Gastric Protruded Lesions on Endoscopy and Endoscopic Ultrasonography Images.2023Clinical and translational gastroenterology
  10. Advanced gastric adenocarcinoma misdiagnosed as gastric stromal tumor.2023Gastrointestinal endoscopy
  11. Deubiquitylation of Rab35 by USP32 promotes the transmission of imatinib resistance by enhancing exosome secretion in gastrointestinal stromal tumours.2023Oncogene
  12. N6-methyladenosine modification regulates imatinib resistance of gastrointestinal stromal tumor by enhancing the expression of multidrug transporter MRP1.2022Cancer letters
  13. Prediction of the Ki-67 expression level and prognosis of gastrointestinal stromal tumors based on CT radiomics nomogram.2022International journal of computer assisted radiology and surgery
  14. Comparison of Computed Tomography Features of Gastric and Small Bowel Gastrointestinal Stromal Tumors With Different Risk Grades.2022Journal of computer assisted tomography
Chinese-language papers (not in the count)1
  1. [Relationship between ripretinib concentration and the prognosis of advanced gastrointestinal stromal tumors in China: a multicenter study].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
Earlier papers (2016–2020)9
  1. A novel nomogram for predicting liver metastasis in patients with gastrointestinal stromal tumor: a SEER-based study.2020BMC surgery
  2. HIF-1α regulates cellular metabolism, and Imatinib resistance by targeting phosphogluconate dehydrogenase in gastrointestinal stromal tumors.2020Cell death & disease
  3. Circulating tumor cells in whole process management of gastrointestinal stromal tumor in a real-life setting.2020Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  4. Intracellular concentration and transporters in imatinib resistance of gastrointestinal stromal tumor.2019Scandinavian journal of gastroenterology
  5. [Clinicopathological analysis of gastrointestinal stromal tumors with PDGFRA mutations].2019Zhonghua bing li xue za zhi = Chinese journal of pathology
  6. Association of Imatinib Plasma Concentration and Single-nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors.2018Molecular cancer therapeutics
  7. Clinical Application of Circulating Tumor DNA in the Genetic Analysis of Patients with Advanced GIST.2018Molecular cancer therapeutics
  8. Comparison of treatment outcomes between laparoscopic and endoscopic surgeries for relatively small gastric gastrointestinal stromal tumors.2018Surgical oncology
  9. [A Chinese multi-center study on the significance of monitoring imatinib plasma concentration in patients with gastrointestinal stromal tumor before and after administration].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status3
  1. Safety of Robotic Surgery for GISTs at Special Anatomic SitesRecruitingNCT07405125Lead sponsorN/AStart 2026-02
  2. A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant NodulesStatus unknownNCT04143048Lead sponsorStart 2019-09
  3. Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)RecruitingNCT07379047Study sitePhase 2/Phase 3Start 2026-05

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 8 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
8
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 1120232024: 1120242025: 002025

10 hospitals in Nanjing for neuroblastoma352 hospitals in China for neuroblastoma

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/Paraganglioma
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT07195500

    Age 6 months to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

  2. Recruiting
    Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma
    Phase
    Not given
    Started
    2022-07
    Registry
    NCT07064746

    Age Not stated to 18 years (registered criteria)

    Led by Jiangsu Province Hospital; 1 listed hospital as study siteNanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiology / nuclear medicinePathology / laboratory medicineGastroenterology / hepatologyNeurosurgery
Papers it led8
  1. Prediction of MYCN amplification status in neuroblastoma using radiomics: a systematic review and meta-analysis.2026Acta radiologica (Stockholm, Sweden : 1987)
  2. Combination of Losartan and Platinum Nanoparticles with Photothermal Therapy Induces Immunogenic Cell Death Effective Against Neuroblastoma.2024International journal of nanomedicine
  3. FAM201A encodes small protein NBASP to inhibit neuroblastoma progression via inactivating MAPK pathway mediated by FABP5.2023Communications biology
  4. Coexpression Network Analysis-Based Identification of Critical Genes Differentiating between Latent and Active Tuberculosis.2022Disease markers
  5. Differentiating Benign from Malignant Renal Tumors Using T2- and Diffusion-Weighted Images: A Comparison of Deep Learning and Radiomics Models Versus Assessment from Radiologists.2022Journal of magnetic resonance imaging : JMRIRCT
  6. Value of non-Gaussian diffusion imaging with a fractional order calculus model combined with conventional MRI for differentiating histological types of cervical cancer.2022Magnetic resonance imaging
  7. Exosomes derived from hypoxic bone marrow mesenchymal stem cells rescue OGD-induced injury in neural cells by suppressing NLRP3 inflammasome-mediated pyroptosis.2021Experimental cell research
  8. EIF4A3-induced circular RNA ASAP1 promotes tumorigenesis and temozolomide resistance of glioblastoma via NRAS/MEK1/ERK1-2 signaling.2021Neuro-oncology
Chinese-language papers (not in the count)1
  1. [Neuroblastoma-like schwannoma of the lung: report of a case].2024Zhonghua bing li xue za zhi = Chinese journal of pathology
Earlier papers (2016–2020)1
  1. Autophagy activated by tuberin/mTOR/p70S6K suppression is a protective mechanism against local anaesthetics neurotoxicity.2017Journal of cellular and molecular medicine
All its trials on ClinicalTrials.gov, any status2
  1. Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis and Staging of Neuroblastoma and Pheochromocytoma/ParagangliomaRecruitingNCT07195500Lead sponsorStart 2024-12
  2. Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of NeuroblastomaRecruitingNCT07064746Lead sponsorStart 2022-07

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Nanjing for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)1
  1. [Ewing's sarcoma of central nervous system: a clinicopathological analysis of six cases].2023Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 24 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 1.4%.

Papers led
24
2021–2025
Trials led
8
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
7
led by another institution
Papers led per year
2021: 5520212022: 5520222023: 5520232024: 2220242025: 552025

7 hospitals in Nanjing for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 13

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2025-12
    Registry
    NCT07294625

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 4 listed hospitals as study sitesNanjing, Shanghai, Xi'an, Xuzhou, Zhengzhou

  2. Recruiting
    A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06497738

    Age 65 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesChangzhou, Nanjing, Nantong

  3. Recruiting
    Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
    Phase
    Phase 4
    Started
    2024-02
    Registry
    NCT07907211

    Age 18 years to 70 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  4. Not yet recruiting
    Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    Early phase 1
    Started
    2026-07
    Registry
    NCT07628595

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  5. Not yet recruiting
    RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07113496

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  6. Not yet recruiting
    LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma
    Phase
    N/A
    Started
    2024-07
    Registry
    NCT06472479

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province Hospital; 2 listed hospitals as study sitesHefei, Nanjing, Zhengzhou

  7. Recruiting
    A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
    Phase
    Phase 1
    Started
    2025-12
    Registry
    NCT07179679

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengde, Chongqing, Guangzhou, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Xi'an

  8. Recruiting
    A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06083207

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Nanjing, Nanning, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an, Xuzhou

  9. Recruiting
    OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
    Phase
    Phase 1/Phase 2
    Started
    2023-10
    Registry
    NCT06182696

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Nanjing, Shanghai, Wuhan

  10. Recruiting
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    Phase
    Phase 4
    Started
    2022-03
    Registry
    NCT05201781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an

  11. Recruiting
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Registry
    NCT04973605

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changsha, Chongqing, Fuzhou, Hangzhou, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xiamen, Zhengzhou

  12. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

  13. Not yet recruiting
    A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)
    Phase
    Phase 1
    Started
    2022-04
    Registry
    NCT05181501

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangzhou, Hefei, Nanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskDrug combinationsRelapse & resistance
Papers it led24
  1. A Nomogram for Predicting Progression-Free Survival in Primary Extramedullary Multiple Myeloma Using Routine Laboratory Variables.2026Acta haematologica
  2. Impact of CD34+ cell infusion dose on immune reconstitution and survival in multiple myeloma after autologous stem cell transplantation.2026Leukemia & lymphoma
  3. Exosome-transmitted HSPA9 facilitates bortezomib resistance by targeting TRIP13/USP1 signaling in multiple myeloma.2025Cell communication and signaling : CCSFree full text
  4. Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy.2025Cell death & diseaseFree full text
  5. HSPA9 contributes to tumor progression and ferroptosis resistance by enhancing USP14-driven SLC7A11 deubiquitination in multiple myeloma.2025Cell reports
  6. Huachansu Injection induces ferroptosis in multiple myeloma through NRF2/HO-1 signaling pathway.2025Journal of ethnopharmacology
  7. LY6E as a new prognostic biomarker of multiple myeloma-related bone disease.2025Scientific reportsFree full text
  8. Simultaneous occurrence of multiple myeloma and acute myeloid leukemia: Case report and literature review.2024Cancer genetics
  9. An inflammatory response-related gene signature can predict the prognosis and impact the immune infiltration of multiple myeloma.2024Clinical and experimental medicineFree full text
  10. Survival trends and prognostic factors of patients with newly diagnosed multiple myeloma accompanied with extramedullary disease.2023Annals of medicineFree full text
  11. Identification of evolutionary mechanisms of myelomatous effusion by single-cell RNA sequencing.2023Blood advancesFree full text
  12. Liquid extramedullary disease in multiple myeloma strongly predicts a poor prognosis and is associated with bortezomib resistance gene upregulation.2023Clinica chimica acta; international journal of clinical chemistry
  13. Single-cell transcriptomic atlas throughout anti-BCMA CAR-T therapy in patients with multiple myeloma.2023Frontiers in immunologyFree full text
  14. Identification of long noncoding RNA NEAT1 as a key gene involved in the extramedullary disease of multiple myeloma by bioinformatics analysis.2023Hematology (Amsterdam, Netherlands)
  15. Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma.2022Chinese medical journalFree full text
  16. Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma.2022Clinical epigeneticsFree full text
  17. Pomalidomide-based therapy for extramedullary multiple myeloma.2022Hematology (Amsterdam, Netherlands)
  18. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma.2022Journal for immunotherapy of cancerFree full text
  19. LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma.2022Leukemia research
  20. Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.2021Annals of medicineFree full text
  21. Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib.2021Cell death & diseaseFree full text
  22. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma.2021Hematology (Amsterdam, Netherlands)
  23. Clinical significance of CD200 expression in newly diagnosed multiple myeloma patients and dynamic changing during treatment.2021Leukemia & lymphoma
  24. The iron chelator deferoxamine decreases myeloma cell survival.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)20
  1. [The Mechanism of Iron in Lymphocyte and Plasma Cell Diseases--Review].2025Zhongguo shi yan xue ye xue za zhi
  2. [Progress in metabolomics of multiple myeloma].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  3. [Prognostic value of high-risk cytogenetic abnormalities inmultiple myeloma].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  4. [Prognostic value of circulating plasma cell in newly diagnosed multiple myeloma treated with bortezomib, lenalidomide, and dexamethasone].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  5. [The Prognostic Value of Del(1p32) in Patients with Newly Diagnosed Multiple Myeloma].2024Zhongguo shi yan xue ye xue za zhi
  6. [Cytoplasmic light-chain immunofluorescence combined with FISH in bone marrow smears to detect cytogenetic abnormalities in multiple myeloma].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  7. [The prognosis and related factors impacting renal response in newly diagnosed multiple myeloma patients with renal impairment].2024Zhonghua yi xue za zhi
  8. [The therapeutic effect and prognostic value of oligoclonal bands after autologous stem cell transplant in patients with multiple myeloma].2024Zhonghua yi xue za zhi
  9. [The characteristics and impact on prognosis of cytopenia after anti-BCMA-CAR-T therapy in patients with relapsed and refractory multiple myeloma].2024Zhonghua yi xue za zhi
  10. [Analysis of Long-Term Prognostic Factors Based on Nutritional Status in Patients with Multiple Myeloma].2023Zhongguo shi yan xue ye xue za zhi
  11. [The Risk and Survival Analysis of Multiple Malignancies in Hematologic Malignancy Patients: A Single Chinese Center Retrospective Study, 2009 through 2017].2023Zhongguo shi yan xue ye xue za zhi
  12. [Clinical characteristics and prognosis of newly diagnosed multiple myeloma patients with FGFR3 gene mutations].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  13. [Validation of the prognostic value of the Mayo MASS and R2-ISS staging systems in patients newly diagnosed with multiple myeloma: A single-center study].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  14. [The impact of low T3 syndrome on the prognosis of patients with newly diagnosed multiple myeloma].2023Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  15. [Clinical Characteristics of Multiple Myeloma Patients with Early Relapse].2022Zhongguo shi yan xue ye xue za zhi
  16. [Effect of Celastrol Based on IRAK4/ERK/p38 Signaling Pathway on Proliferation and Apoptosis of Multiple Myeloma Cells].2022Zhongguo shi yan xue ye xue za zhi
  17. [Comparison of etoposide combined with G-CSF and cyclophosphamide combined with G-CSF in mobilization of autologous peripheral hematopoietic stem cells in patients with newly diagnosed multiple myeloma].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  18. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  19. [Analysis of Serum Metabonomics in Patients with Multiple Myeloma Based on Liquid Chromatography-Mass Spectrometry].2021Zhongguo shi yan xue ye xue za zhi
  20. [Myelomatous pleural effusion treated with daratumumab and intrapleural bortezomib: a case report].2021Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status24
  1. Safety and Efficacy of RN9101 in the Treatment of Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07628595Lead sponsorEarly phase 1Start 2026-07
  2. RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic MalignanciesNot yet recruitingNCT07113496Lead sponsorPhase 1Start 2025-08
  3. A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT07294625Lead sponsorEarly phase 1Start 2025-12
  4. A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple MyelomaRecruitingNCT06497738Lead sponsorStart 2024-05
  5. LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06472479Lead sponsorN/AStart 2024-07
  6. SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary DiseaseCompletedNCT05900882Lead sponsorPhase 2Start 2022-07
  7. A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaStatus unknownNCT03815383Lead sponsorPhase 1Start 2019-04
  8. Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple MyelomaRecruitingNCT07907211Lead (inferred)Phase 4Start 2024-02
  9. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  10. A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell TumorsRecruitingNCT07179679Study sitePhase 1Start 2025-12
  11. A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Study sitePhase 1/Phase 2Start 2024-07
  12. OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMMRecruitingNCT06182696Study sitePhase 1/Phase 2Start 2023-10
  13. A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2)Not yet recruitingNCT05181501Study sitePhase 1Start 2022-04
  14. A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruitingNCT05201781Study sitePhase 4Start 2022-03
  15. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Study sitePhase 1/Phase 2Start 2021-09
  16. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  17. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  18. A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)Status unknownNCT05066646Study sitePhase 1/Phase 2Start 2020-04
  19. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03758417Study sitePhase 2Start 2019-01
  20. Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Study sitePhase 3Start 2019-01
  21. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03860038Study sitePhase 2Start 2019-01
  22. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT03952091Study sitePhase 3Start 2019-03
  23. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)CompletedNCT03217812Study sitePhase 3Start 2017-11
  24. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03234972Study sitePhase 3Start 2017-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led no English-language PubMed papers on B-cell acute lymphoblastic leukaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution

3 hospitals in Nanjing for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-08
    Registry
    NCT07113496

    Age 18 years to Not stated (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  2. Recruiting
    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
    Phase
    Phase 2
    Started
    2022-01
    Registry
    NCT05334823

    Age 3 years to 21 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 9 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 2.2%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 3320222023: 3320232024: 1120242025: 222025

1 hospital in Nanjing for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunosuppressive treatmentThrombopoietin drugsStem cell transplant
Papers it led9
  1. Combining immunosuppressive therapy with low dosage eltrombopag in Chinese patients with severe aplastic anemia: mild aggravation of hepatic injury.2025Annals of hematologyFree full text
  2. Comparison of Haploidentical-Hematopoietic Stem Cell Transplantation Using Modified Post-Transplantation Cyclophosphamide and Eltrombopag Combined With Immunosuppression for the Treatment of Severe Aplastic Anemia.2025Transplantation and cellular therapy
  3. Loeys-Dietz syndrome with concomitant aplastic anemia.2024Annals of hematology
  4. Comparison of haploidentical-allogeneic hematopoietic stem cell transplantation and intensive immunosuppressive therapy for patients with severe aplastic anemia with an absolute neutrophil count of zero: a retrospective study.2023Annals of hematology
  5. Prolonged use of eltrombopag in patients with severe aplastic anemia in the real world.2023Clinical and experimental medicine
  6. Transfusion-dependent non-severe aplastic anemia: characteristics and outcomes in the clinic.2023Frontiers in immunologyFree full text
  7. A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia.2022Annals of hematology
  8. Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag.2022Frontiers in immunologyFree full text
  9. Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?2022Transplantation and cellular therapy
Chinese-language papers (not in the count)1
  1. [The efficacy of eltrombopag plus cyclosporine A in patients with transfusion-dependent non-severe aplastic anemia: a retrospective study from single center].2022Zhonghua nei ke za zhi

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 22 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 5.5%.

Papers led
22
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 4420222023: 3320232024: 7720242025: 552025

1 hospital in Nanjing for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesDiagnosis & prognosisLymphoma & cancer-related HLHEBV & infection triggers
Departments in papersPathology / laboratory medicine
Papers it led22
  1. Endothelial Activation and Stress Index Serves as a Predictor for Survival in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Multicenter Cohort Study of Jiangsu Cooperative Lymphoma Group.2025American journal of hematology
  2. Elevated fibrosis‑4 index is associated with 30-day mortality in adult hemophagocytic lymphohistiocytosis patients.2025Annals of hematologyFree full text
  3. Predicting six-month mortality in adult hemophagocytic lymphohistiocytosis with machine learning: a prognostic approach utilizing laboratory data.2025Annals of medicineFree full text
  4. Epidemiological, clinical characteristics and prognostic factors analysis of adult patients with hemophagocytic lymphohistiocytosis in a Chinese hospital.2025Frontiers in immunologyFree full text
  5. Perforin Expression and Natural Killer-Cell Proportion as Biomarkers in Secondary Hemophagocytic Lymphohistiocytosis.2025Medical science monitor : international medical journal of experimental and clinical researchFree full text
  6. Comparison of different treatment regimens and analysis of prognostic factors in secondary hemophagocytic lymphohistiocytosis in adults: A single-center retrospective study.2024Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  7. Association of albumin to urea nitrogen ratio with 30-day mortality in adult hemophagocytic lymphohistiocytosis: a retrospective cohort study.2024Annals of hematology
  8. Association of a decreased platelet count with poor survival in patients with adult secondary hemophagocytic lymphohistiocytosis.2024Annals of hematology
  9. The clinical significance and prognostic value of serum beta-2 microglobulin in adult lymphoma-associated hemophagocytic lymphohistiocytosis: a multicenter analysis of 326 patients.2024Annals of hematology
  10. Clinicopathological characteristics, prognostic factors, and outcomes of elderly patients with lymphoma-associated hemophagocytic lymphohistiocytosis: A multicenter analysis.2024Cancer medicineFree full text
  11. Histiocytic necrotizing lymphadenitis with hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 5 cases.2024Immunity, inflammation and diseaseFree full text
  12. Machine Learning of Laboratory Data in Predicting 30-Day Mortality for Adult Hemophagocytic Lymphohistiocytosis.2024Journal of clinical immunology
  13. Prognostic value of the albumin-bilirubin score in patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis.2023Frontiers in immunologyFree full text
  14. The Clinical Significance and Prognostic Role of Whole-Blood Epstein-Barr Virus DNA in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis.2023Journal of clinical immunology
  15. Clinical value of soluble fms-like tyrosine kinase 1 (sFlt-1) in adult secondary hemophagocytic lymphohistiocytosis.2023Journal of the Chinese Medical Association : JCMAFree full text
  16. Spectrum and trigger identification of hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 555 cases.2022Frontiers in immunologyFree full text
  17. Characteristics and prognostic value of pleural effusion in secondary hemophagocytic lymphohistiocytosis.2022International journal of hematologyFree full text
  18. Development of Laboratory Parameters-Based Formulas in Predicting Short Outcomes for Adult Hemophagocytic Lymphohistiocytosis Patients with Different Underlying Diseases.2022Journal of clinical immunology
  19. The prevalence and prognosis of hyponatraemia in non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis.2022Leukemia & lymphoma
  20. Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome associated with reactivation of Epstein-Barr virus leading to secondary hemophagocytic lymphohistiocytosis in an HLA-B*5801-negative patient.2021Indian journal of dermatology, venereology and leprology
  21. Ferritin index is a strong prognostic marker in adult hemophagocytic lymphohistiocytosis.2021International journal of clinical practice
  22. Clinical features of 47 secondary hemophagocytic lymphohistiocytosis patients complicated with capillary leak syndrome.2021International journal of hematologyFree full text
Chinese-language papers (not in the count)6
  1. [Clinical analysis of nine cases of hemophagocytic lymphohistiocytosis during pregnancy: characteristics, therapeutic strategies, and maternal-infant outcomes].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  2. [Intravascular large B-cell lymphoma of the nasal turbinate presenting with hemophagocytic lymphohistiocytosis: a case report and literature review].2025Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  3. [Effect of Plasma Epstein-Barr Virus Nucleic Acid Loads on the Clinical Features and Prognosis in Adult Secondary Hemophagocytic Lymphohistiocytosis].2024Zhongguo shi yan xue ye xue za zhi
  4. [Clinical analysis of cytomegalovirus infection-associated hemophagocytic lymphohistiocytosis in five patients without underlying diseases].2024Zhonghua nei ke za zhi
  5. [Expression and diagnostic value of lymphocyte subsets and activation status in non-Hodgkin's lymphoma-associated hemophagocytic lymphohistiocytosis].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
  6. [Expression and Clinical Significance of Serum sFas/sFasL in Patients with Secondary Hemophagocytic Lymphohistiocytosis].2023Zhongguo shi yan xue ye xue za zhi
All its trials on ClinicalTrials.gov, any status2
  1. Trial of DA-EPOCH Regimen for NHL With HLHStatus unknownNCT01818908Lead sponsorPhase 2Start 2012-06
  2. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))CompletedNCT07034209Study sitePhase 2Start 2023-04
More papers found outside PubMed (not counted)13
  1. 759 | UPDATED OUTCOMES OF P‐GEMD IN TREATMENT‐NAÏVE EARLY‐STAGE NON‐UPPER AERO‐DIGESTIVE TRACT OR ADVANCED‐STAGE EXTRANODAL NK/T CELL LYMPHOMA2025Hematological Oncologyarticle
  2. A Phase 2 Multicenter Study of Pegaspargase in Combination with Gemcitabine, Etoposide, Mitoxantrone Hydrochloride Liposome, and Dexamethasone (P-GEMD) for Newly Diagnosed Early Non-Upper Aero-Digestive Tract or Advanced Stage Extranodal NK2024Bloodconference-abstract
  3. Circulating 25-hydroxyvitamin D in secondary hemophagocytic lymphohistiocytosis2024Venue not listedpreprint
  4. Endothelial Activation and Stress Index (EASIX) to Predict Survival in T or NK Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis2024Bloodconference-abstract
  5. Pathological Subtyping, Outcomes, and Survival Trends of Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 464 Patients2024Bloodconference-abstract
  6. Clinical Significance of Serum High-Density Lipoprotein Cholesterol and Its Dynamic Change in Patients with Lymphoma-Associated Hemophagocytic Lymphohistiocytosis2023Bloodconference-abstract
  7. High Prevalence of MYD88 and CD79B Mutations and PD-L1 Alterations in Bone Marrow Large B Cell Lymphoma Associated with Hemophagocytic Lymphohistiocytosis2023Bloodconference-abstract
  8. Histiocytic Necrotizing Lymphadenitis with Hemophagocytic Lymphohistiocytosis: A Single-Center Analysis of Five Cases2023Bloodconference-abstract
  9. Liver function tests in patients with secondary hemophagocytic lymphohistiocytosis: prevalence and impact on in-hospital mortality2023Research Squarepreprint
  10. PRELIMINARY RESULTS OF GEMCITABINE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE LIPOSOME AND DEXAMETHASONE REGIMEN FOR NEWLY DIAGNOSED EARLY NUAT OR ADVANCED STAGE ENKTL2023Hematological Oncologyarticle
  11. The Clinical Significance and Prognostic Value of Serum Beta-2 Microglobulin in Adult Lymphoma-Associated Hemophagocytic Lymphohistiocytosis: A Multicenter Analysis of 326 Patients2023Bloodconference-abstract
  12. Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up2022Bloodarticle
  13. Prognostic and Predictive Value of the Pretreatment Albumin-bilirubin Score for Short and Long-term Survival in Patients With Non-Hodgkin Lymphoma-associated Hemophagocytic Lymphohistiocytosis With Hepatic Injuries2022Research Squarepreprint

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Nanjing for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Nanjing for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Age-related severity and distribution of haemophilic arthropathy of the knee, ankle and elbow among Chinese patients with haemophilia.2020Haemophilia : the official journal of the World Federation of Hemophilia

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 4 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 112025

2 hospitals in Nanjing for myasthenia gravis93 hospitals in China for myasthenia gravis

No open trial on myasthenia gravis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesBiologic & complement drugsAntibodies & diagnosisCrisis & intensive care
Departments in papersNeurologyMedical oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 3 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.8%.

Papers led
3
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

3 hospitals in Nanjing for moyamoya disease47 hospitals in China for moyamoya disease

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Enrolling by invitation
    Fufang Tongluo Decoction as an Adjunct to Aspirin and Atorvastatin for Ischemic Moyamoya Disease
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT07875335

    Age 18 years to 60 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  2. Enrolling by invitation
    Clinical Safety and Efficacy Evaluation of the Blood-cooling and Stasis-removing Formula as an Adjunct to Atorvastatin in the Treatment of Hemorrhagic Moyamoya Disease.
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT07894640

    Age 18 years to 60 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

  3. Enrolling by invitation
    Clinical Evaluation of the Safety and Efficacy of "Buyan Huan Wu Tang" Combined With Atorvastatin in the Treatment of Atypical Pneumonia
    Phase
    Early phase 1
    Started
    2024-12
    Registry
    NCT07906652

    Age 18 years to 60 years (registered criteria)

    Led by Jiangsu Province HospitalNanjing

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesGeneticsImaging & blood flowRevascularisation surgery
Departments in papersNeurosurgeryRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 2 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.1%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Nanjing for Takayasu arteritis108 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 10 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 1.0%.

Papers led
10
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 2220232024: 2220242025: 222025

15 hospitals in Nanjing for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRheumatology & immunology

Over half of these papers are lab or animal studies.

Papers it led10
  1. Nobiletin's role in idiopathic pulmonary fibrosis via the PI3K/AKT/MDM2/p53 signaling pathway.2026Naunyn-Schmiedeberg's archives of pharmacology
  2. The aspartate superpathway in gut microbiota-related metabolic pathways mediates immune cell protection against COPD and IPF: a Mendelian randomization analysis.2025Aging
  3. Identification of potential mechanisms of Schisandrin B in the treatment of idiopathic pulmonary fibrosis by integrating network pharmacology and experimental validation.2025Naunyn-Schmiedeberg's archives of pharmacology
  4. The causal relationship between genetically predicted blood metabolites and idiopathic pulmonary fibrosis: A bidirectional two-sample Mendelian randomization study.2024PloS one
  5. TOM5 regulates the mitochondrial membrane potential of alveolar epithelial cells in organizing pneumonia.2024Redox report : communications in free radical research
  6. Integrating bioinformatic resources to identify characteristics of rheumatoid arthritis-related usual interstitial pneumonia.2023BMC genomics
  7. Hesperidin inhibits lung fibroblast senescence via IL-6/STAT3 signaling pathway to suppress pulmonary fibrosis.2023Phytomedicine : international journal of phytotherapy and phytopharmacology
  8. Interleukin-19 Aggravates Pulmonary Fibrosis via Activating Fibroblast through TGF-β/Smad Pathway.2022Mediators of inflammation
  9. Efficacy of YAP1-gene Knockdown to Inhibit Alveolar-Epithelial-Cell Senescence and Alleviate Idiopathic Pulmonary Fibrosis (IPF).2021Cancer genomics & proteomics
  10. An increased risk of lung cancer in combined pulmonary fibrosis and emphysema patients with usual interstitial pneumonia compared with patients with idiopathic pulmonary fibrosis alone: a systematic review and meta-analysis.2021Therapeutic advances in respiratory disease
Earlier papers (2016–2020)5
  1. Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production: a therapeutic implication for idiopathic pulmonary fibrosis.2020Aging
  2. MUTYH Deficiency Is Associated with Attenuated Pulmonary Fibrosis in a Bleomycin-Induced Model.2020Oxidative medicine and cellular longevity
  3. [Analysis of clinical characteristics of 21 cases of acute fibrinous and organizing pneumonia].2020Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  4. Gastric Acid and Pepsin Work Together in Simulated Gastric Acid Inhalation Leading to Pulmonary Fibrosis in Rats.2019Medical science monitor : international medical journal of experimental and clinical research
  5. Effects of panax notoginseng saponin on the pathological ultrastructure and serum IL-6 and IL-8 in pulmonary fibrosis in rabbits.2018Journal of cellular biochemistry

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 4 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 222025

8 hospitals in Nanjing for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurologyRadiology / nuclear medicine
Papers it led4
  1. Differed brain spontaneous neural activity between limb-onset and bulbar-onset amyotrophic lateral sclerosis patients.2025Brain research bulletin
  2. Early cortical alterations and neuropsychological mechanisms in amyotrophic lateral sclerosis.2025NeuroImage. Clinical
  3. The presence and clinical significance of autoantibodies in amyotrophic lateral sclerosis: a narrative review.2024Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  4. Anti-neurofascin 186 antibody in amyotrophic lateral sclerosis: a case report.2023Acta neurologica Belgica
Chinese-language papers (not in the count)1
  1. [Advance in research on pathogenetic genes for amyotrophic lateral sclerosis].2022Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Nanjing for Fabry disease85 hospitals in China for Fabry disease

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease
    Phase
    Not given
    Started
    2025-11
    Registry
    NCT07187440

    Age 7 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Nanjing, Shantou, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led1
  1. Rare Diseases in Glycosphingolipid Metabolism.2022Advances in experimental medicine and biology
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseRecruitingNCT07187440Study siteStart 2025-11

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

4 hospitals in Nanjing for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led no English-language PubMed papers on Behçet disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Nanjing for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Dural sinus thrombosis and giant pulmonary artery aneurysm in paediatric Behçet's disease.2020Clinical and experimental rheumatology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

8 hospitals in Nanjing for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology
Papers it led2
  1. Delta corticomedullary apparent diffusion coefficient on MRI as a biomarker for prognosis in IgA nephropathy.2025Renal failure
  2. Targeted release of budesonide in primary IgA nephropathy.2024Lancet (London, England)
Earlier papers (2016–2020)2
  1. New insight into the management of IgA nephropathy.2018Clinical and experimental nephrology
  2. Plasma microRNA signature of patients with IgA nephropathy.2018Gene
All its trials on ClinicalTrials.gov, any status4
  1. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  2. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  3. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  4. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led 1 of the 30 English-language PubMed papers on Gaucher disease with an author in mainland China, 2021–2025: 3.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Nanjing for Gaucher disease41 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

3 hospitals in Nanjing for osteogenesis imperfecta59 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Papers it led1
  1. A novel de novo mutation in COL1A1 leading to osteogenesis imperfecta confirmed by zebrafish model.2021Clinica chimica acta; international journal of clinical chemistry

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution

10 hospitals in Nanjing for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07282353

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBaoji, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Hangzhou, Harbin, Hefei, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shiyan, Taizhou, Tianjin, Xi'an, Xiamen, Zhanjiang, Zhengzhou

  2. Recruiting
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    Phase
    Phase 2/Phase 3
    Started
    2023-02
    Registry
    NCT05749822

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan’an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Effect of Huagantongluofang, a Chinese Traditional Medicine, in Hepatic Fibrogenesis in a Mouse Model of Biliary Cirrhosis.2017Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology
All its trials on ClinicalTrials.gov, any status3
  1. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCARecruitingNCT07282353Study sitePhase 3Start 2025-12
  2. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisRecruitingNCT05749822Study sitePhase 2/Phase 3Start 2023-02
  3. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CholangitisActive, not recruitingNCT06174402Study sitePhase 2/Phase 3Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Nanjing for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Nanjing for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Lipopolysaccharide enhances ADAR2 which drives Hirschsprung's disease by impairing miR-142-3p biogenesis.2018Journal of cellular and molecular medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led no English-language PubMed papers on inherited epidermolysis bullosa in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Nanjing for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Successful Treatment of Esophageal Stenosis in a Patient with Dystrophic Epidermolysis Bullosa Using Balloon Dilation.2017Journal of vascular and interventional radiology : JVIR

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led no English-language PubMed papers on hereditary angioedema in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Nanjing for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersENT / head & neck surgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 2 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 3.4%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

5 hospitals in Nanjing for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

1 hospital in Nanjing for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

江苏省人民医院(南医大一附院)

Jiangsu Province Hospital

南京

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
First Affiliated Hospital of Nanjing Medical University; Jiangsu Province Hospital of Chinese Medicine; First Affiliated Hospital with Nanjing Medical University; Jiangsu Province Hospital; Jiangsu Province Hospital of Traditional Chinese Medicine; 江苏省人民医院

Suggest a correctionDownload the data